GB SCIENCES INC - Form 10-Q SEC filing

0001445866-17-001661.txt : 20171120 0001445866-17-001661.hdr.sgml : 20171120 20171117181119 ACCESSION NUMBER: 0001445866-17-001661 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171120 DATE AS OF CHANGE: 20171117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GB SCIENCES INC CENTRAL INDEX KEY: 0001165320 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 593733133 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55462 FILM NUMBER: 171212227 BUSINESS ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 BUSINESS PHONE: (844) 843-2569 MAIL ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 FORMER COMPANY: FORMER CONFORMED NAME: Growblox Sciences, Inc. DATE OF NAME CHANGE: 20140603 FORMER COMPANY: FORMER CONFORMED NAME: Signature Exploration & Production Corp. DATE OF NAME CHANGE: 20080602 FORMER COMPANY: FORMER CONFORMED NAME: Diabetic Treatment Centers of America, Inc. DATE OF NAME CHANGE: 20040812 10-Q 1 gblx-20170930.htm 10-Q GB SCIENCES INC - Form 10-Q SEC filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 10-Q

__________________________

(Mark One)

ý	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission file number: 000-55462

GB SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of Incorporation or organization)

593733133

(IRS Employer I.D. No.)

3550 W. Teco Avenue

Las Vegas, Nevada 89118

Phone: (866) 721-0297

(Address and telephone number of

principal executive offices)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ý Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ý Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

(Do not check if a smaller Reporting Company)

Smaller Reporting Company ý

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act). ¨ Yes ý No

There were 128,300,407 shares of common stock, par value $0.0001 per share, outstanding as of November 15, 2017.

GB SCIENCES, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017

INDEX

PART I – FINANCIAL INFORMATION		Page

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets at September 30, 2017 (unaudited) and March 31, 2017	3

	Condensed Consolidated Statements of Operations (unaudited) for the Three and Six Months Ended September 30, 2017 and 2016	4

	Condensed Consolidated Statements of Cash Flows (unaudited) for the Six Months Ended September 30, 2017 and 2016	5

	Notes to Condensed Consolidated Financial Statements (unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16
Item 4.	Controls and Procedures	17

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	17
Item 1A	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	19
Item 6.	Exhibits	19

SIGNATURES		20

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

GB SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

	30-Sep-17	31-Mar-17


CURRENT ASSETS:
Cash and cash equivalents	`$971,286`	`$2,692,953`
Accounts Receivable	`248,265`	`-`
Inventory	`532,752`	`89,037`
Prepaid expenses	`561,066`	`166,378`
TOTAL CURRENT ASSETS	`2,313,369`	`2,948,368`
Property and Equipment, Net	`11,296,124`	`8,642,677`
Deposits	`1,257,746`	`1,203,305`
Other Assets	`292,289`	`212,529`
TOTAL ASSETS	`$15,159,528`	`$13,006,879`
CURRENT LIABILITIES:
Accounts Payable	`$76,235`	`$157,152`
Accrued Interest	`100,294`	`48,969`
Accrued Liabilities	`605,184`	`468,710`
Convertible Notes Payable, net of unamortized discount of $4.6 million and $1 million at September 30, 2017 and March 31, 2017, respectively	`530,893`	`2,734`
TOTAL CURRENT LIABILITIES	`1,312,606`	`677,565`
Convertible Notes Payable	`507`	`155,312`
Capital Lease Obligations	`6,182,181`	`3,771,321`
TOTAL LIABILITIES	`7,495,294`	`4,604,198`
Commitments and Contingencies (Note 7)
STOCKHOLDERS' (DEFICIT)/ EQUITY:
Common Stock, $0.0001 par value, 200,000,000 shares authorized, 127,927,431 and 124,406,818 shares issued and outstanding at September 30, 2017 and March 31, 2017	`12,793`	`12,441`
Additional Paid In Capital	`49,012,336`	`43,569,864`
Accumulated Deficit	`(41,490,290)`	`(35,257,045)`
TOTAL GB SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY	`7,534,839`	`8,325,260`
Non-controlling interest	`129,395`	`77,421`
TOTAL (DEFICIT)/EQUITY	`7,664,234`	`8,402,681`
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY	`$15,159,528`	`$13,006,879`

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	For the Three Months Ended September 30,		For the Six Months Ended September 30,
	2017	2016	2017	2016

NET REVENUE	`$136,646`	`$-`	`$190,745`	`$-`
GENERAL AND ADMINISTRATIVE EXPENSES	`2,779,370`	`2,197,557`	`5,660,035`	`3,405,338`
LOSS FROM OPERATIONS	`(2,642,724)`	`(2,197,557)`	`(5,469,290)`	`(3,405,338)`
OTHER INCOME (EXPENSE)
Interest Expense	`(530,082)`	`(297,929)`	`(786,798)`	`(456,460)`
Other Income/(Expense)	`(5,769)`	`(10,479)`	`(45,182)`	`(23,075)`
Total other expense	`(535,851)`	`(308,408)`	`(831,980)`	`(479,535)`
NET LOSS	`(3,178,575)`	`(2,505,965)`	`(6,301,270)`	`(3,884,873)`
Net income/(loss) attributable to non-controlling interest	`(33,495)`	`(38,661)`	`(68,025)`	`(76,862)`
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	`$(3,145,080)`	`$(2,467,304)`	`$(6,233,245)`	`$(3,808,011)`
Net loss per share - basic and diluted	`$(0.02)`	`$(0.04)`	`$(0.05)`	`$(0.06)`
Weighted average common shares outstanding - basic and diluted	`127,794,766`	`67,920,941`	`126,724,132`	`59,043,603`

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)


	Six Months Ended September 30,
	2017	2016
OPERATING ACTIVITIES:
Net loss	`$(6,301,270)`	`$(3,884,873)`
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	`385,184`	`137,133`
Stock-based compensation	`1,211,218`	`1,785,315`
Amortization of debt discount and beneficial conversion feature	`450,983`	`316,745`
Loss on disposal	`-`	`5,572`
Changes in operating assets and liabilities:
Accounts receivable	`(248,265)`	`-`
Prepaid expenses and other assets	`(394,688)`	`42,886`
Inventory	`(443,715)`	-
Accounts payable	`(80,917)`	`33,716`
Accrued expenses	`170,050`	`(129,807)`
Net cash used in operating activities	`(5,251,420)`	`(1,693,313)`
INVESTING ACTIVITIES:
Purchase of property and equipment	`(513,271)`	`(957,925)`
Change in deposits and other assets	`(134,561)`	`(21,856)`
Net cash used in investing activities	`(647,832)`	`(979,781)`
FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	`4,550`	`4,140,354`
Proceeds from non-controlling interest	`120,000`	`165,000`
Proceeds from convertible notes payable	`4,119,500`	`500,000`
Payments under long-term obligations	`(66,465)`	`(94,898)`
Other financing activities	`-`	`(154)`
Net cash provided by financing activities	`4,177,585`	`4,710,302`
Net change in cash and cash equivalent	`(1,721,667)`	`2,037,208`
CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD	`2,692,953`	`34,824`
CASH AND CASH EQUIVALENT AT END OF PERIOD	`$971,286`	`$2,072,032`
Non-cash transactions:
Stock issued to settle payables	`$-`	`$590,777`
Stock issued upon partial conversion of long-term note payable	`$184,731`	`$500,000`
Stock issued to settle legal obligations	`$-`	`$410,840`
Capital lease obligation	`$2,525,000`	`$3,900,000`
Stock and warrants issued upon amendment of long-term note	`$-`	`$875,663`


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1 – Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2018. The balance sheet at March 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2017.

Principles of Consolidation

The condensed consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. These reclassifications had no effect on the reported financial position, results of operations or cash flows of the Company.

Significant Accounting Policies

A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2017.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued amended accounting guidance that changes the accounting for leases and requires expanded disclosures about leasing activities. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability, measured on a discounted basis, at the commencement date for all leases with terms greater than twelve months. Lessor accounting will remain largely unchanged, other than certain targeted improvements intended to align lessor accounting with the lessee accounting model and with the updated revenue recognition guidance issued in 2014. Lessees and lessors must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The amended guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018, and early application is

Table of Contents

permitted. The Company expects that adoption of this guidance will result in the recognition of rig-of-use assets and related obligations.

The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is required to adopt the guidance on January 1, 2018 and will apply the cumulative catch-up transition method. The transition adjustment to be recorded to stockholders' equity upon adoption of the new standard is not expected to be material. The Company is currently evaluating the impact of ASC 606 when adopted on its consolidated financial position and result of operations.

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Note 2 – Going Concern

The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of approximately $41.5 million at September 30, 2017. In addition, the Company has consumed cash in its operating activities of approximately $5.2 million for the six months ended September 30, 2017 compared to $1.7 million for the same period last year. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no assurances that the Company will be successful in securing capital necessary to achieve its goals.

In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.

Note 3 – Convertible Notes

In March 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $965,500. The Notes are payable within three years of issuance and are convertible into 3,862,000 shares of the Company’s common stock. The Company also issued 3,862,000 common stock warrants to the Note holders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.60 per share for a period of three years. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $416,733 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and note. In addition to this discount related to the beneficial conversion feature, an additional discount of $548,767 was recorded based on the fair value of the warrants attached to the note. This value was derived using the Black-Scholes valuation model.

During the three months ended June 30, 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $1,034,500. The Notes are payable within three years of issuance and are convertible into 4,138,000 shares of the Company’s common stock. The Company also issued 4,138,000 common stock warrants to the Note holders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common

Table of Contents

stock of the Company at an exercise price of $0.60 per share for a period of three years. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $487,957 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and note. In addition to this discount related to the beneficial conversion feature, an additional discount of $480,236 was recorded based on the fair value of the warrants attached to the note. This value was derived using the Black-Scholes valuation model.

In July, 2017, the Company entered into a Placement Agent’s Agreement with a third-party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per share for the period of three years.

During the three months ended September 30, 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $3,085,000. The Notes are payable within three years of issuance and are convertible into 12,340,000 shares of the Company’s common stock. The Company also issued 12,340,000 common stock warrants to the Note holders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.65 per share for a period of three years. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $1,541,797 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and note. In addition to this discount related to the beneficial conversion feature, an additional discount of $1,532,335 recorded based on the fair value of the warrants attached to the note. This value was derived using the Black-Scholes valuation model.

Note 4– Note Payable

The Company entered into a Note Purchase Agreement, dated May 12, 2015 and effective as of June 8, 2015, with Pacific Leaf Ventures, LP (“Pacific Leaf”), pursuant to which Pacific Leaf has made installment loans (the “Loans”) to the Company in the aggregate amount of $1.75 million. The purpose of the financing is to provide for the acquisition and installation of an operating facility, equipment and other tangible assets by GB Sciences Nevada, LLC (“GBSN”). Such facility and equipment was dedicated to the cultivation of cannabis and the extraction of oils and other constituents present in cannabis, subject at all times to Nevada legal requirements. The note is convertible at the option of the holder into common shares at a conversion price of $0.50, subject to anti-dilution adjustments.

To evidence the Loans, the Company issued to Pacific Leaf a 6% senior secured convertible promissory note (the “Note”), bearing interest at the rate of 6% per annum, payable quarterly. All outstanding principal and interest due under the Note were due and payable on May 12, 2020. The Company was required to prepay the outstanding principal amount of the Note on a quarterly basis in an amount equal to 50% of the cash flow (accrued EBITDA) of GBSN attributable to our percentage interest in GBSN no later than the earlier to occur of (a) the fifth (5th) business day following receipt of a distribution of the Company's Share of GBSN’s EBITDA for the calendar quarter in question, or (b) thirty (30) days following the end of the calendar quarter in question, with the first such prepayment to be made not later than July 31, 2015 with respect to the quarter ending June 30, 2015. In order to induce the Pacific Leaf to extend the loan to the Company and to secure the payment and performance of all of the Secured Obligations, the Company agreed to grant Pacific Leaf a security interest in certain of its assets and enter into the lending agreement.

On February 8, 2016, the Company entered into the Amended and Restated 6% Senior Convertible Promissory Note (“Amended Note”) with Pacific Leaf. The amended agreement modifies the 6% Senior Secure Convertible Promissory Note dated May 12, 2015 and effective as of June 8, 2015, in the principal amount of $1.75 million.

Per the terms of the amended agreement, Pacific Leaf may make up to $1.0 million in additional advances to the Company under the Amended Note bringing the total in the aggregate to $2.75 million. The note is convertible at the option of the holder into common shares at a conversion price of $0.25, subject to anti-dilution adjustments. The Company has an option to prepay the Amended Note, without premium or penalty, in whole or in part, with accrued interest to the date of such prepayment.

Table of Contents

Until the payment in full of the Amended Note, Pacific Leaf or its designee have the option (the “Option”) to purchase up to a 20% membership interest in GBSN for a purchase price equal to $100,000 for each 2% of membership interest purchased (i.e., $1,000,000 if the Option is exercised in full), provided that the Option may not be exercised for less than a 1% membership interest in GBSN.

In connection with the Amended Note, the Company also entered into the Amended and Restated Royalty Agreement with Pacific Leaf dated and effective as of February 8, 2016. Per the terms of the Amended Royalty Agreement, the royalty rate at any time shall equal to the sum of (i) 9.1%, and (ii) the percentage calculated by dividing the amount advanced in excess of $1.75 million by $1.0 million, multiplied by the gross revenues of GBSN. On the earlier of (i) the seventh anniversary of the royalty payment date, or (ii) the date that all amounts outstanding under the Amended Note have been paid in full, the royalty rate shall be reduced by 50%.

On June 13, 2016, the Company received notice from the Pacific Leaf that it had elected to convert $500,000 of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 2,000,000 shares of its common stock ($500,000 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness pursuant to the Note was reduced by $500,000.

On August 4, 2016, the Company entered into the Second Omnibus Amendment ("Second Amendment") of its existing agreements with Pacific Leaf. The Second Amendment eliminates Pacific Leaf's option to purchase up to a 20% membership interest in GBSN and reduces Pacific Leaf's existing royalty rate to 16.4% of the gross sales revenue of GBSN. It also caps maximum aggregate royalty payments to be made to Pacific Leaf at $2,420,000 with respect to any calendar year. In consideration of the amended terms, Pacific Leaf and its designees received 1,000,000 shares of the Company's common stock and a five-year warrant to purchase 1,500,000 shares of the Company's common stock at $0.36 per share resulting in related expense of approximately $0.9 million.

On October 4, October 20, November 1, and November 10, 2016, the Company received notices the Pacific Leaf that it had elected to convert total of $1,776,750 of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 7,107,000 shares of its common stock ($1,776,750 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness pursuant to the Note was reduced by $1,776,750.

On January 24, and February 22, 2017, the Company received additional notices from Pacific Leaf Ventures, LP (“Pacific Leaf”) that it had elected to convert $413,085 ($317,938 in principal and $95,145 in accrued interest) of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 1,652,332 shares of its common stock ($413,083 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness pursuant to the Note was reduced to $0.2 million.

On May 12, 2017, the Company received notice from Pacific Leaf Ventures, LP (“Pacific Leaf”) that it had elected to convert $184,805 ($154,805 principal and $30,000 accrued interest) of the Company’s indebtedness to Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Note was reduced by $184,805.

Note 5 – Capital Lease

In July 2016, an entity associated with Pacific Leaf Partners, LLC completed the purchase of the building housing the Company’s cultivation facility at 3550 W. Teco Ave., Las Vegas, NV. In connection with the purchase, the Company entered into the Amended Lease Agreement for an initial term of ten and a half years with one option to extend the lease for five years, or until December 31, 2030. The monthly rent payments per the Amended Lease Agreement are $40,000 through December 31, 2017. Commencing January 1, 2018, the monthly rent payments will increase by 3% per annum through the expiration of the lease. The Company analyzed the transaction in accordance with the applicable accounting guidance determining that the aggregate amount of $3.9 million met the requirements for capitalization. The building has been capitalized and is included in property and equipment, net balance with related obligations included as part of current and non-current liabilities. The obligation recorded is based upon the present value of the future minimum lease payments discounted at an 11.6% interest rate.

Table of Contents

In August 2017, GB Sciences Louisiana, LLC entered into the Lease Agreement with Petroleum Drive Investment, LLC for 36,125 square feet of interior space on approximately 5.38 acres of land located at 18350 Petroleum Drive, Baton Rouge, LA 70809. The Lease Agreement is for an initial term of five years with two options to extend the lease for five years, or until June 30, 2032. The monthly rent payments per the Lease Agreement are $25,588 through June 30, 2022. If the Company exercises its first and second options to extend, monthly rent payments will increase to $28,147 beginning August 1, 2022, and to $30,966 beginning August 1, 2027. The Company analyzed the transaction in accordance with the applicable accounting guidance determining that the aggregate amount of $2.5 million met the requirements for capitalization. The building has been capitalized and is included in property and equipment, net balance with related obligations included as part of current and non-current liabilities. The obligation recorded is based upon the present value of the future minimum lease payments discounted at a 10.2% interest rate.

Note 6 – Capital Transactions

During the six months ended September 30, 2017, the Company issued an aggregate of 3,520,613 shares of common stock, as follows:

The Company issued 2,191,994 shares of its common stock to a third-party brokerage firm as a result of a cashless exercise of 2,281,000 compensation warrants at the exercise price of $0.01 per share and recorded a related expense of $0.6 million

On May 12, 2017, the Company received notice from Pacific Leaf Ventures, LP (“Pacific Leaf”) that it had elected to convert $184,805 ($154,805 principal and $30,000 accrued interest) of the Company’s indebtedness to Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 739,220 shares of its common stock ($184,805 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness to Pacific Leaf pursuant to the Note has been reduced by $184,805.

The Company issued 485,871 shares in exchange for consulting services and recorded a related expense of $0.1 million. The Company also issued 82,528 shares of common stock to employees and recorded an expense of $0.02 million.

The Company issued 21,000 shares of its common stock in connection with the exercise of warrants at $0.20 per share.

Options and Warrants

During the six months ended September 30, 2017, the Company issued 550,000 stock options under the 2014 Equity Incentive Plan to various consultants. The options are exercisable upon vesting for a period of 10 years from issuance at an exercise price ranging from $0.24 to $0.35 per share per share. The Company has recognized total of $0.04 million in share-based compensation expense related to options vested to date.

During the six months ended September 30, 2017, the Company issued 250,000 stock options under the 2014 Equity Incentive Plan to its employees. The options are exercisable upon vesting for a period of 10 years from issuance at an exercise price ranging from $0.27 to $0.28 per share per share. The Company has recognized total of $0.06 million in share-based compensation expense related to options vested to date.

During the six months ended September 30, 2017, the Company issued warrants to purchase 4,138,000 shares of its common stock at the price of $0.60 per share and warrants to purchase 12,340,000 shares of its common stock at the price of $0.65 per share for the period of three years to various holders of its convertible notes. Convertible notes have combined face value of $4,119,500. The Company recorded a discount of $2,012,571 based on the fair value of the warrants attached to the notes. This value was derived using the Black-Scholes valuation model.

Table of Contents

Note 7 – Commitments and Contingencies

On September 18, 2017 GB Sciences finalized its agreement with Louisiana State University (“LSU”) AgCenter to be the sole operator of the LSU’s medical marijuana program. The LSU Board of Supervisors entered into a five-year agreement—that has an option to renew for two additional five-year terms—with GB Sciences.

The contract includes the Company’s commitment to make a minimum financial contribution to the LSU AgCenter in the amount of $3.4 million, or a 10% commission of gross receipts, in addition to annual research investments of $500,000 to the LSU AgCenter.

The monetary contributions would be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, which AgCenter would retain 50% of those rights. As of September 2017, GB Sciences made payments totaling $500,000 toward its obligations under the agreement.

From time to time, the Company may become involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.

Note 8 – Loss per Share

The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 58,197,413 and 39,882,413 of potentially dilutive common shares at September 30, 2017 and March 31, 2017, respectively. However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.

Note 9 – Related Party Transactions

During the fiscal year ended March 31, 2017, the Company entered into a consulting contract with Quantum Shop, a Company owned by a relative of one of the Company’s executives. Per the terms of the agreement, Quantum Shop is to provide GB Sciences with research, design, development, fabrication, and production services. During the year ended March 31, 2017, the Company made a payment of $50,000 to the Quantum Shop in relation to the services provided. During the six months ended September 30, 2017, additional payments of $149,903 were made to Quantum Shop in relation to the services provided.

During the year ended March 31, 2017, the Company entered into an advisory agreement with Electrum Partners, LLC, a company whose President resides on GB Sciences’ Board of Directors and serves as a Chair of the Audit Committee. The agreement has a term of one year and is renewable for a successive one-year period. During the six months ended September 30, 2017, the Company made payments totaling $75,562 to Electrum Partners, LLC and issued 283,296 shares of its restricted stock.

During the six months ended September 30, 2017, the Company entered into a consulting contract with Monica Poss, a relative of one of the Company’s executives. Per the terms of the agreement, Ms. Poss is to provide GB Sciences with advisory services. The Company made payments of $10,927 and issued 17,650 shares of our common stock at an expense of $4,500 relating to services provided during the six months ended September 30, 2017.

Table of Contents

Note 10 – Subsequent Events

Private Placement Agreement

Subsequent to September 30, 2017, the Company raised additional $800,000 under an existing Placement Agent’s Agreement with a third-party brokerage firm to offer for sale a maximum of up to 6,500 units at the price of $1,000 per unit for the combined total of $6.5 million. Each unit consists of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per shares for the period of three years. As a result, the Company issued 3,200,000 warrants.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts” or “continue” , which list is not meant to be all-inclusive and other such negative terms and comparable technology. These forward-looking statements, include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include among other things: (1)product demand, market and customer acceptance of GB Sciences products, equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified personnel, (iv)competition pricing and development difficulties, (v) general industry and market conditions and growth rates, unexpected natural disasters, and other factors, which we have little or no control: and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”). The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this report.

The following discussion highlights the Company’s results of operations and the principal factors that have affected our financial condition, as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis is based on the Company’s unaudited financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read this discussion and analysis together with such financial statements and the related notes thereto.

Overview

The Company seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.

Although we believe that maximum shareholder value will ultimately be achieved through the development, production and marketing of certified cannabinoid medicines, therapies and treatments, in order to generate cash flow and near-term profitability, we intend to cultivate and dispense cannabis for medical purposes in both Nevada and other states which permit such sales and in which we and our operating partners are able to obtain cultivation and dispensing licenses.

We seek to become a trusted producer of consistent and efficacious medicinal strains and products, combining both cannabinoids and terpenes, which we intend to market in those states within the United States and in other countries where the sale of medical cannabis products are permitted. In addition, subject to obtaining Food and Drug Administrative (FDA) certification, we intend to market our cannabinoid-based drug discoveries on a world-wide basis.

We were incorporated in the State of Delaware on April 4, 2001, under the name “Flagstick Venture, Inc.” On March 28, 2008, stockholders owning a majority of our outstanding common stock approved changing our then name “Signature Exploration and Production Corp.” as our business model had changed.

Table of Contents

On March 13, 2014, we entered into a definitive assets purchase agreement for the acquisition of assets, including the Growblox™ cultivation technology which resulted in a change in our corporate name on April 4, 2014, from Signature Exploration and Production Corporation to Growblox Sciences, Inc.

Effective December 12, 2016, the Company amended its Certificate of Corporation pursuant to shareholder approval as reported in the Form 8-K filed on October 14, 2016. Pursuant to the amendment the Company’s name was changed from Growblox Sciences, Inc. to GB Sciences, Inc.

Plan of Operation

The Company is cultivating cannabis using innovative, but conventional methods in its wholly owned subsidiary, GB Sciences Nevada, LLC (“GBSN”). On January 4, 2017, GBSN received a State Registration Certificate (“Certificate”) for its 28,000-sq. ft. cannabis cultivation facility located in Las Vegas, NV. The receipt of the Certificate allows the Company to cultivate medical cannabis. Phase 1 of the GBSN cultivation facility opened with 200 grow lights. When all phases of construction are completed, the facility is expected to generate revenues of approximately $10 million per year. Completion of all Phases of this facility is dependent upon the availability of capital to complete construction. The Company has made completion of all Phases of this facility its number one priority. In May 2017, cultivation facility harvested its first cannabis. As a result of the harvest and subsequent harvests, the Company recorded net revenue of approximately $0.2 million for the six months ended September 30, 2017.

On October 4, 2016, we acquired a 60% interest in a Nevada Medical Marijuana Production License with an option of up to 80%. A production license enables us to convert cannabis plants into to oils and extracts that are suitable for creating medical compounds as well as consumer products. This license is critical and essential to our plan of producing cannabis-based medicines, and must be integrated into our cultivation facility to ensure quality control standards and efficiency in our production of cannabis medicines.

On March 31, 2017, we entered into an agreement with Arizona-based company, Kush Cups, to produce cannabis-infused products in the state of Nevada. Cannabis for production will be grown in our Cultivation Labs facility in Las Vegas, NV. We will distribute cannabis-infused Keurig-compatible K-Cups, hot and cold brew coffees as well as infused teas.

We expect our products to compete well in the marketplace because of the considerable efforts we have made in the plant genetics and tissue culturing of our proprietary strains of cannabis. And, we are the exclusive Nevada grower of Kyle Kushman's proprietary marijuana strains which have been highly rated top sellers in California.

The current emphasis on near-term cash flow allows us to plan for exploiting the potential of our science assets. We recently formed Growblox Life Sciences, LLC and have retained Fenwick & West, a Silicon Valley based law firm focusing on life sciences and high technology companies with a nationally top-ranked intellectual property practice, to development strategies for the protection of the Company's intellectual property. On October 11, 2016, we filed the first of several planned patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC. The current provisional patent application covers complex-cannabinoid-containing mixtures capable of enhancing dopamine secretion and protecting neurons from the mitochondria-induced free radical damage that occurs during disease progression in the brains of patients with Parkinson's disease, Alzheimer's disease, Lewy Body Dementia, and Huntington's disease, among others. At this time, the Company plans to seek partners in the pharmaceutical industry or alternatively venture funding to advance these cannabis-based formulations to clinical testing and commercialization.

On December 13, 2016, Growblox Life Sciences, LLC licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure. Licensing this TRPV1 patent underscores the Company’s drug discovery commitment to targeting the non-classical cannabinoid receptors, beyond the usual CB1 and CB2 receptors

Table of Contents

On February 1, 2017, we filed second patent application for the Treatment of Chronic Arthritis, Crohn's Disease, Inflammatory Bowel Disease, and Asthma; Proprietary Cannabinoid-Containing Complex Mixtures for the Treatment of Inflammatory Disorders. The current provisional patent application covers cannabinoid-containing complex mixtures ("CCCM") capable of preventing and treating a spectrum of inflammatory disorders. The application focuses on the use of CCCM to disrupt the signaling pathways in certain immune cells that lead to the initiation and maintenance of inflammatory responses. Both common and uncommon inflammatory disorders, ranging from chronic arthritis to acute responses to insect stings, are likely to be effectively targeted by this therapeutic approach.

On May 23, 2017, we filed third patent application for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures ("MCCM"). The current provisional patent application covers myrcene-containing complex mixtures capable of targeting the non-traditional cannabinoid receptor, TRPV1. Our latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016.

On July 1, 2017, GBSN received a provisional Nevada recreational cannabis license for branded recreational products. The decision to sell to the recreational market through the addition of GB Sciences’ own trusted-ingredient retail brands, strengthens the Company’s vertically-integrated strategy of controlling product quality and purity from seed-to-sale. Premium flower and medical-grade oils for use in vape pens and tinctures will be sold under the Cultivation Labs banner.

RESULTS OF OPERATIONS

The following table sets forth certain of our Statements of Operations data:

	For the Three Months Ended September 30,		For the Six Months Ended September 30,
	2017	2016	2017	2016

Net revenue	$ 136,646	$ -	$ 190,745	$ -
General and administrative expenses	2,779,370	2,197,557	5,660,035	3,405,338
Other Income/(Expense)	(535,851)	(308,408)	(831,980)	(479,535)
Net loss attributable to non-controlling interest	(33,495)	(38,661)	(68,025)	(76,862)
Net Loss	$ (3,145,080)	$ (2,467,304)	$ (6,233,245)	$ (3,808,011)

Comparison of the Three Months Ended September 30, 2017 and 2016

Net Revenue

The Company recorded net revenue of approximately $0.1 million for the three months ended September 30, 2017 as compared to no operating revenue for the same period in prior year. Increase in net revenue is due the Company’s cultivation facility located in Las Vegas, NV harvesting its first cannabis in May 2017 and subsequent harvests.

General and administrative expenses

General and administrative expenses increased $0.6 million to $2.8 million for the three months ended September 30, 2017 compared to $2.2 million for the three months ended September 30, 2016. The increase is attributable in part to a $0.5 million increase in consulting and advisory expense related primarily to payment of commissions pursuant to the terms of a private placement agreement and other consulting fees related to investor relations expenses.

Other expense

Table of Contents

Total other expense increased by $0.2 million compared to the same period in prior year. The increase is primarily due to amortization of the debt discount related to the beneficial conversion features discount recorded on the convertible debt.

Comparison of the Six Months Ended September 30, 2017 and 2016

Net Revenue

The Company recorded net revenue of approximately $0.2 million for the six months ended September 30, 2017 as compared to no operating revenue for the same period in prior year. Increase in net revenue is due the Company’s cultivation facility located in Las Vegas, NV harvesting its first cannabis in May 2017 and subsequent harvests.

General and administrative expenses

General and administrative expenses increased $2.3 million to $5.7 million for the six months ended September 30, 2017 compared to $3.4 million for the six months ended September 30, 2016. The increase is attributable in part to a $1.9 million increase in consulting and advisory expense related primarily to payment of commissions pursuant to the terms of a private placement agreement and issuance of compensation warrants combined with $0.4 million increase in payroll and related expenses.

Other expense

Total other expense increased by $0.3 million compared to the same period in prior year. The increase is primarily due to amortization of the debt discount related to the beneficial conversion features discount recorded on the convertible debt.

LIQUIDITY AND CAPITAL RESOURCES

Current Liquidity

The Company will need additional capital to implement its strategies. There is no assurance that it will be able to raise the amount of capital needed for future growth plans. Even if financing is available, it may not be on terms that are acceptable. If unable to raise the necessary capital at the times required, the Company may have to materially change the business plan, including delaying implementation of aspects of the business plan or curtailing or abandoning the business plan. The Company represents a speculative investment and investors may lose all of their investment. In order to be able to achieve the strategic goals, the Company needs to further expand its business and financing activities. Based upon the cash position, it is necessary to raise additional capital by the end of the next quarter in order to continue to fund current operations. These factors raise substantial doubt about the ability to continue as a going concern. The Company is pursuing several alternatives to address this situation, including the raising of additional funding through equity or debt financings. In order to finance existing operations and pay current liabilities over the next twelve months, the Company will need to raise additional capital. No assurance can be given that the Company will be able to operate profitably on a consistent basis, or at all, in the future.

The principal sources of liquidity to date have been cash generated from sales of debt and equity securities and loans.

At September 30, 2017, cash was $1.0 million, other current assets excluding cash were $1.3 million, and our working capital was $1.0 million. At the same time, current liabilities were approximately $1.3 million and consisted principally of $0.6 million in accrued liabilities and $0.5 million in notes payable. At March 31, 2017, the Company had a cash balance of $2.7 million, other current assets excluding cash were $0.3 million and our working capital was $2.3 million. Current liabilities were approximately $0.7 million, which consisted principally of $0.5 million in accrued liabilities and $0.2 million in accounts payable.

Sources and Uses of Cash

Operating Activities

Table of Contents

Net cash used in operating activities was $5.3 million for the six months ended September 30, 2017, as compared to net cash used of $1.7 million for the six months ended September 30, 2016. We anticipate that cash flows from operations may be insufficient to fund business operations for the next twelve-month period. Accordingly, we will have to generate additional liquidity or cash flow to fund our current and anticipated operations. This will likely require the sale of additional common stock or other securities. There is no assurance that we will be able to realize any significant proceeds from such sales, if at all.

Investing Activities

During the six months ended September 30, 2017 and 2016, the Company used $0.6 million and $1.0 million, respectively, of cash in investing activities. The cash used in investing activities during the six months ended September 30, 2017 and 2016 was primarily for the purchase of property and equipment.

Financing Activities

During the six months ended September 30, 2017 and 2016, cash flows from financing activities totaled $4.2 million and $4.7 million, respectively. Cash flows from financing activities for the six months ended September 30, 2017 related primarily to $4.1 million in proceeds from the issuance of convertible notes and $0.1 million in proceeds from non-controlling interests. Cash flows from financing activities for the six months ended September 30, 2016 related primarily to $4.1 million in proceeds from the issuance of common stock and warrants, $0.5 million in proceeds from the issuance of convertible notes, and $0.2 million in proceeds from non-controlling interests.

GOING CONCERN

The unaudited interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize assets and discharge liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of approximately $41.5 million as of September 30, 2017, and further losses are anticipated in the development of the business raising substantial doubt about the ability to continue as a going concern. The ability to continue as a going concern is dependent upon generating profitable operations in the future and/or obtaining the necessary financing to meet obligations and repay liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and/or private placements of debt and equity securities. The financials do not include any adjustments relating to the recoverability and reclassification of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.

VARIABLES AND TRENDS

In the event the Company is able to obtain the necessary financing to progress with its business plan, the Company expects expenses to increase significantly to grow the business. Accordingly, the comparison of the financial data for the periods presented may not be a meaningful indicator of future performance and must be considered in light of these circumstances.

CRITICAL ACCOUNTING POLICIES

A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2017.

ITEM 3.Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Table of Contents

The Company maintains disclosure controls and procedures that are designed to ensure that material information required to be disclosed in the periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. At the end of the quarter ended September 30, 2017, the Company carried out an evaluation, under the supervision and with the participation of management, including the principal executive officer and the principal financial officer, of the effectiveness of the design and operation of disclosure controls and procedures, as defined in Rule 13(a)-15(e) and Rule 15d-15(e) under the 1934 Act. Based on this evaluation, management concluded that as of September 30, 2017 the disclosure controls and procedures were not effective due to material weaknesses as no member of our board of directors qualifies as an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act.

Limitations on Effectiveness of Controls and Procedures

Management, including the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Controls

During the fiscal quarter ended September 30, 2017, there have been no changes in the internal controls over financial reporting that have materially affected or are reasonably likely to materially affect the internal controls over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.Legal Proceedings

From time to time, the Company also becomes involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.

ITEM 1A.Risk Factors

There are no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the SEC.

ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds

Table of Contents

During the six months ended September 30, 2017, the Company issued an aggregate of 3,520,613 shares of common stock, as follows:

The Company issued 21,000 shares of its common stock in connection with the exercise of warrants at $0.20 per share.

Options and Warrants

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not Applicable.

ITEM 5. Other Information

None.

ITEM 6. Exhibits

Table of Contents

In reviewing the agreements included as exhibits to this Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:

should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and

were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Form 10-Q and the Company’s other public filings, which are available without charge through the SEC’s website at http://www.sec.gov.

The following exhibits are included as part of this report:

Exhibit Number		Description of Exhibit
3.1		Articles of Incorporation (Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)
3.2		Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.2 to Form S-1/A No. 333-82580 filed with the Commission on October 6, 2014 and Exhibit 3.2 to Form 10-K No. 333-82580 filed with the Commission on June 27, 2014)
3.3		Bylaws (Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)
31.1		Certification of Principal Executive Officer and Pursuant to Rule 13a-14
31.2		Certification of Principal Financial Officer Pursuant to Rule 13a-14
32.1*		CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2*		CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

* This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

Table of Contents

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GB SCIENCES, INC.

November 20, 2017	By:	/s/ John Poss
	John Poss, Chief Executive Officer (Principal Executive Officer)

	GB SCIENCES, INC.

November 20, 2017	By:	/s/ Ksenia Griswold
	Ksenia Griswold, Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 gblx_ex31z1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Poss, certify that:

1.I have reviewed this quarterly report on Form 10-Q of GB Sciences, Inc.;

2.Based on my knowledge, the quarterly report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Date: November 20, 2017

/s/ John Poss

John Poss, Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 gblx_ex31z2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ksenia Griswold, certify that:

1.I have reviewed this quarterly report on Form 10-Q of GB Sciences, Inc.;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Date: November 20, 2017

/s/ Ksenia Griswold

Ksenia Griswold, Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 gblx_ex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GB Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Poss, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: November 20, 2017	/s/ John Poss
	John Poss, Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 gblx_ex32z2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GB Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ksenia Griswold, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 20, 2017	/s/ Ksenia Griswold
	Ksenia Griswold, Chief Financial Officer (Principal Financial Officer)

EX-101.CAL 6 gblx-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 gblx-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 gblx-20170930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Research and Development Expense Employee Stock Option Investment Warrants, Exercise Price Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Shares Issued Short Term Promissory Note 5 Stock issued for modification of notes payable Notes Changes in operating assets and liabilities: TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY Well-known Seasoned Issuer Non-Option Equity Instruments, Exercised Short Term Promissory Note 7 Schedule of Short Term Notes and Interest Bearing Advance Basis of Presentation Note 10 - Subsequent Events Amortization of debt discount and beneficial conversion feature LOSS FROM OPERATIONS LOSS FROM OPERATIONS TOTAL CURRENT ASSETS TOTAL CURRENT ASSETS Document Fiscal Year Focus Subsequent Event Teco Facility Lease Stock and warrants issued upon amendment of long-term note Debt Instrument, Maturity Date Short Term Promissory Note 6 Stock issued for modification of notes payable Legal Entity [Axis] Note 1 - Basis of Presentation and Significant Accounting Policies Common Stock, Shares Authorized Common Stock, $0.0001 par value, 200,000,000 shares authorized, 127,927,431 and 124,406,818 shares issued and outstanding at September 30, 2017 and March 31, 2017 Entity Address, City or Town Trading Symbol Non-Option Equity Instruments, Granted Stock Issued During Period, Value, Issued for Services Equity Award Maximum Capital Lease Obligations Description of Lessee Leasing Arrangements, Capital Leases Interest Stock issued for modification of notes payable Class of Warrant, Exercise Price Reclassifications Stock issued to settle payables Non-cash transactions: OPERATING ACTIVITIES: Weighted average common shares outstanding - basic and diluted OTHER INCOME (EXPENSE) Common Stock, Shares, Outstanding Commitments and Contingencies (Note 7) Public Float Stock Issued During Period, Shares, Share-based Compensation Debt Instrument, Convertible, Number of Equity Instruments Policies Capital lease obligation Stock issued to upon conversion of long-term note payable Represents the monetary amount of Stock issued to upon conversion of long-term note payable, during the indicated time period. Proceeds from non-controlling interest Loss on disposal Loss on disposal Depreciation and amortization Accumulated Deficit Entity Address, Postal Zip Code Details Other Commitments Discount Rate Short Term Promissory Note 4 Stock issued for modification of notes payable Debt Instrument, Face Amount Equity Component Debt Instrument [Axis] Statement [Line Items] Note 7 - Commitments and Contingencies Note 5 - Capital Lease Stock and warrants issued upon amendment of long-term note Represents the monetary amount of Stock and warrants issued upon amendment of long-term note, during the indicated time period. Net change in cash and cash equivalent Net change in cash and cash equivalent Net cash used in investing activities Net cash used in investing activities Prepaid expenses and other assets Prepaid expenses and other assets Net loss per share - basic and diluted TOTAL GB SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY TOTAL GB SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY TOTAL LIABILITIES TOTAL LIABILITIES Accrued Liabilities {1} Accrued Liabilities Cash and cash equivalents CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENT AT END OF PERIOD Amendment Description Award Type [Axis] Range [Axis] Royalty Agreement Amended Terms Represents the description of Royalty Agreement Amended Terms, during the indicated time period. Significant Accounting Policies Note 6 - Capital Transactions Note 2 - Going Concern Proceeds from convertible notes payable Purchase of property and equipment Purchase of property and equipment TOTAL (DEFICIT)/EQUITY TOTAL (DEFICIT)/EQUITY Convertible Notes Payable {1} Convertible Notes Payable TOTAL CURRENT LIABILITIES TOTAL CURRENT LIABILITIES Local Phone Number Current with reporting Filer Category Minimum Range Scenario, Unspecified Stock issued to settle legal obligations Represents the monetary amount of Stock issued to settle legal obligations, during the indicated time period. INVESTING ACTIVITIES: Deposits {1} Deposits CURRENT ASSETS: Contained File Information, File Number Period End date SEC Form Minimum Financial Contribution Represents the Minimum Financial Contribution, during the indicated time period. Plan Name [Axis] Area of Real Estate Property Debt Instrument, Payment Terms Debt Instrument, Interest Rate, Stated Percentage Pacific Leaf Ventures Lp Stock issued for modification of notes payable Debt Instrument, Convertible, Beneficial Conversion Feature Note 9 - Related Party Transactions Convertible Notes Payable, net of unamortized discount of $4.6 million and $1 million at September 30, 2017 and March 31, 2017, respectively Entity Incorporation, State Country Name Tax Identification Number (TIN) Related Party Electrum Partners LLC Stock issued for modification of notes payable Quantum Shop Represents the Quantum Shop, during the indicated time period. Expiration Period Stock Issued During Period, Shares, Issued for Services Debt Conversion, Original Debt, Amount Area of Land Lease Arrangement, Type [Axis] Major Types of Debt Securities Statement Note 3 - Convertible Notes Proceeds from issuance of common stock and warrants Accounts payable Adjustments to reconcile net loss to net cash used in operating activities: Net income/(loss) attributable to non-controlling interest Common Stock, Par or Stated Value Per Share Accounts Payable {1} Accounts Payable Prepaid expenses Inventory Number of common stock shares outstanding Annual Research Investments Represents the Annual Research Investments, during the indicated time period. Stock Granted, Value, Share-based Compensation Stock Issued During Period, Shares, New Issues Allocated Share-based Compensation Expense Common Stock Scenario [Axis] Accounts receivable Accounts receivable NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC. NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC. Common Stock, Shares, Issued Debt Instrument, Unamortized Discount STOCKHOLDERS' (DEFICIT)/ EQUITY: Voluntary filer GB Sciences Louisiana Lease Stock and warrants issued upon amendment of long-term note Long-term Debt, Gross Debt Security [Axis] Recent Accounting Pronouncements Note 4- Note Payable Change in deposits and other assets Change in deposits and other assets Inventory {1} Inventory Other Income/(Expense) NET REVENUE Additional Paid In Capital Accrued Interest Other Assets Entity Address, State or Province Entity Address, Address Line One Document Fiscal Period Focus Registrant CIK Officer Options, Granted 2014 Equity Incentive Plan Schedule of Short Term Notes and Interest Bearing Advance Stock Issued During Period, Shares, Other Debt Instrument, Convertible, Terms of Conversion Feature Debt Instrument, Convertible, Conversion Price Warrants Outstanding Net cash provided by financing activities Net cash provided by financing activities FINANCING ACTIVITIES: GENERAL AND ADMINISTRATIVE EXPENSES Fiscal Year End Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Gross receipts, commission Represents the Gross receipts, commission, during the indicated time period. Other Commitments [Axis] Options, Grants in Period, Weighted Average Grant Date Fair Value A third-party brokerage firm Stock issued for modification of notes payable Class of Warrant, Outstanding Short Term Promissory Note 1 Stock issued for modification of notes payable Debt Instrument, Name Principles of Consolidation Note 8 - Loss per Share Other financing activities Net cash used in operating activities Net cash used in operating activities Stock-based compensation CURRENT LIABILITIES: Accounts Receivable Subsequent Event Type Related Party [Axis] Warrant Approximate Stock issued for modification of notes payable Property and Equipment, Net Subsequent Event Type [Axis] Related Party Transaction, Amounts of Transaction LSU AgCenter Represents the LSU AgCenter, during the indicated time period. EX-101.PRE 9 gblx-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 gblx-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000090 - Disclosure - Note 4- Note Payable link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 2 - Going Concern link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 9 - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 3 - Convertible Notes link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Note 10 - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Note 5 - Capital Lease link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Note 4- Note Payable (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Note 3 - Convertible Notes (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Note 6 - Capital Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Note 8 - Loss per Share link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Note 1 - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Note 10 - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Note 8 - Loss per Share (Details) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 6 - Capital Transactions link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 7 - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Note 1 - Basis of Presentation and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Note 7 - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Note 9 - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Note 5 - Capital Lease (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Note 2 - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink XML 11 gblx-20170930_htm.xml IDEA: XBRL DOCUMENT 0001165320 2017-04-01 2017-09-30 0001165320 fil:ApproximateMember 2017-09-30 0001165320 fil:ApproximateMember 2017-04-01 2017-09-30 0001165320 fil:ApproximateMember 2016-04-01 2016-09-30 0001165320 fil:ShortTermPromissoryNote1Member 2017-03-31 0001165320 fil:ShortTermPromissoryNote1Member us-gaap:CommonStockMember 2017-03-01 2017-03-31 0001165320 fil:ShortTermPromissoryNote1Member 2017-03-01 2017-03-31 0001165320 fil:ShortTermPromissoryNote1Member 2017-06-30 0001165320 fil:ShortTermPromissoryNote1Member us-gaap:CommonStockMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote1Member 2017-09-30 0001165320 fil:ShortTermPromissoryNote1Member 2017-04-01 2017-09-30 0001165320 2017-09-30 0001165320 2017-07-01 2017-07-31 0001165320 fil:PrivatePlacementOf6ConvertiblePromissoryNotesMember 2017-09-30 0001165320 fil:PrivatePlacementOf6ConvertiblePromissoryNotesMember 2017-04-01 2017-09-30 0001165320 fil:PacificLeafVenturesLpMember 2015-06-08 0001165320 fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 fil:PacificLeafVenturesLpMember 2016-02-08 0001165320 fil:PacificLeafVenturesLpMember 2016-01-01 2016-03-31 0001165320 fil:ShortTermPromissoryNote4Member fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:ShortTermPromissoryNote4Member us-gaap:CommonStockMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote4Member fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 2016-09-30 0001165320 fil:ConvertiblePromissoryNoteMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 us-gaap:CommonStockMember fil:PacificLeafVenturesLpMember 2016-08-01 2016-08-31 0001165320 fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:PacificLeafVenturesLpMember 2016-08-01 2016-08-31 0001165320 us-gaap:WarrantMember fil:PacificLeafVenturesLpMember 2016-08-01 2016-08-31 0001165320 fil:ShortTermPromissoryNote5Member fil:PacificLeafVenturesLpMember 2016-11-10 0001165320 fil:ShortTermPromissoryNote5Member fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:ShortTermPromissoryNote5Member us-gaap:CommonStockMember fil:PacificLeafVenturesLpMember 2016-10-01 2016-11-30 0001165320 fil:ShortTermPromissoryNote5Member fil:PacificLeafVenturesLpMember 2016-10-01 2016-11-30 0001165320 fil:ShortTermPromissoryNote6Member fil:PacificLeafVenturesLpMember 2017-02-22 0001165320 2017-11-15 0001165320 fil:ShortTermPromissoryNote6Member fil:PrincipalMember fil:PacificLeafVenturesLpMember 2017-02-22 0001165320 fil:ShortTermPromissoryNote6Member fil:InterestMember fil:PacificLeafVenturesLpMember 2017-02-22 0001165320 fil:ShortTermPromissoryNote6Member fil:PacificLeafVenturesLpMember 2017-02-28 0001165320 fil:ShortTermPromissoryNote6Member us-gaap:CommonStockMember fil:PacificLeafVenturesLpMember 2017-01-01 2017-02-28 0001165320 fil:ShortTermPromissoryNote6Member fil:PacificLeafVenturesLpMember 2017-01-01 2017-02-28 0001165320 fil:ShortTermPromissoryNote7Member fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member fil:PrincipalMember fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member fil:InterestMember fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:TecoFacilityLeaseMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 fil:TecoFacilityLeaseMember fil:PacificLeafVenturesLpMember 2016-07-01 2016-09-30 0001165320 2017-03-31 0001165320 fil:TecoFacilityLeaseMember fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:GbSciencesLouisianaLeaseMember fil:PacificLeafVenturesLpMember 2017-09-30 0001165320 fil:GbSciencesLouisianaLeaseMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 us-gaap:CommonStockMember 2017-04-01 2017-09-30 0001165320 us-gaap:CommonStockMember fil:AThirdPartyBrokerageFirmMember 2017-04-01 2017-09-30 0001165320 us-gaap:WarrantMember fil:AThirdPartyBrokerageFirmMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member fil:PrincipalMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member fil:InterestMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member us-gaap:CommonStockMember fil:PacificLeafVenturesLpMember 2017-04-01 2017-09-30 0001165320 2017-07-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote7Member fil:PacificLeafVenturesLpMember 2017-05-12 0001165320 us-gaap:WarrantMember 2017-04-01 2017-09-30 0001165320 us-gaap:WarrantMember 2017-09-30 0001165320 fil:N2014EquityIncentivePlanMember 2017-04-01 2017-09-30 0001165320 fil:N2014EquityIncentivePlanMember us-gaap:MinimumMember 2017-04-01 2017-09-30 0001165320 fil:N2014EquityIncentivePlanMember us-gaap:MaximumMember 2017-04-01 2017-09-30 0001165320 us-gaap:EmployeeStockOptionMember fil:N2014EquityIncentivePlanMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote1Member us-gaap:WarrantMember 2017-04-01 2017-09-30 0001165320 fil:ShortTermPromissoryNote1Member us-gaap:WarrantMember 2017-09-30 0001165320 fil:PrivatePlacementOf6ConvertiblePromissoryNotesMember us-gaap:WarrantMember 2017-04-01 2017-09-30 0001165320 2016-07-01 2016-09-30 0001165320 fil:PrivatePlacementOf6ConvertiblePromissoryNotesMember us-gaap:WarrantMember 2017-09-30 0001165320 fil:MinimumFinancialContributionMember fil:LsuAgcenterMember 2017-09-30 0001165320 fil:MinimumFinancialContributionMember fil:LsuAgcenterMember 2017-04-01 2017-09-30 0001165320 fil:AnnualResearchInvestmentsMember fil:LsuAgcenterMember 2017-09-30 0001165320 fil:AnnualResearchInvestmentsMember fil:LsuAgcenterMember 2017-04-01 2017-09-30 0001165320 2016-04-01 2017-03-31 0001165320 fil:QuantumShopMember 2016-04-01 2017-03-31 0001165320 fil:QuantumShopMember 2017-04-01 2017-09-30 0001165320 fil:ElectrumPartnersLlcMember 2017-04-01 2017-09-30 0001165320 us-gaap:OfficerMember 2017-04-01 2017-09-30 0001165320 2016-04-01 2016-09-30 0001165320 us-gaap:SubsequentEventMember 2017-08-11 2017-08-11 0001165320 us-gaap:SubsequentEventMember 2017-07-01 2017-07-31 0001165320 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2017-08-11 2017-08-11 0001165320 2016-03-31 pure iso4217:USD shares iso4217:USD shares utr:sqft utr:acre GB SCIENCES INC 0001165320 --03-31 gblx Yes No No false 2018 Q2 10-Q 2017-09-30 000-55462 Delaware 593733133 3550 W. Teco Avenue Las Vegas Nevada 89118 866 721-0297 Smaller Reporting Company 128300407

971286

2692953

248265

532752

89037

561066

166378

2313369

2948368

11296124

8642677

1257746

1203305

292289

212529

15159528

13006879

76235

157152

100294

48969

605184

468710

4600000

1000000

530893

2734

1312606

677565

507

155312

6182181

3771321

7495294

4604198

0.0001

200000000

127927431

124406818

12793

12441

49012336

43569864

-41490290

-35257045

7534839

8325260

129395

77421

7664234

8402681

15159528

13006879

136646

190745

2779370

2197557

5660035

3405338

-2642724

-2197557

-5469290

-3405338

530082

297929

786798

456460

-5769

-10479

-45182

-23075

-535851

-308408

-831980

-479535

-3178575

-2505965

-6301270

-3884873

-33495

-38661

-68025

-76862

-3145080

-2467304

-6233245

-3808011

-0.02

-0.04

-0.05

-0.06

127794766

67920941

126724132

59043603

-6301270

-3884873

385184

137133

1211218

1785315

450983

316745

-5572

248265

394688

-42886

443715

-80917

33716

170050

-129807

-5251420

-1693313

513271

957925

134561

21856

-647832

-979781

4550

4140354

120000

165000

4119500

500000

66465

94898

-154

4177585

4710302

-1721667

2037208

2692953

34824

971286

2072032

590777

184731 500000 0 410840

2525000

3900000

0 875663

Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2018. The balance sheet at March 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2017.

Principles of Consolidation The condensed consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. These reclassifications had no effect on the reported financial position, results of operations or cash flows of the Company.

Significant Accounting Policies A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2017.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued amended accounting guidance that changes the accounting for leases and requires expanded disclosures about leasing activities. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability, measured on a discounted basis, at the commencement date for all leases with terms greater than twelve months. Lessor accounting will remain largely unchanged, other than certain targeted improvements intended to align lessor accounting with the lessee accounting model and with the updated revenue recognition guidance issued in 2014. Lessees and lessors must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The amended guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018, and early application is permitted. The Company expects that adoption of this guidance will result in the recognition of rig-of-use assets and related obligations. The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is required to adopt the guidance on January 1, 2018 and will apply the cumulative catch-up transition method. The transition adjustment to be recorded to stockholders' equity upon adoption of the new standard is not expected to be material. The Company is currently evaluating the impact of ASC 606 when adopted on its consolidated financial position and result of operations. Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Note 2 – Going Concern The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of approximately $41.5 million at September 30, 2017. In addition, the Company has consumed cash in its operating activities of approximately $5.2 million for the six months ended September 30, 2017 compared to $1.7 million for the same period last year. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no assurances that the Company will be successful in securing capital necessary to achieve its goals. In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.

41500000

5200000

1700000

965500

3862000

0.60

416733

548767

During the three months ended June 30, 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $1,034,500. The Notes are payable within three years of issuance and are convertible into 4,138,000 shares of the Company’s common stock. The Company also issued 4,138,000 common stock warrants to the Note holders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.60 per share for a period of three years. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $487,957 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and note. In addition to this discount related to the beneficial conversion feature, an additional discount of $480,236 was recorded based on the fair value of the warrants attached to the note. This value was derived using the Black-Scholes valuation model. In July, 2017, the Company entered into a Placement Agent’s Agreement with a third-party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per share for the period of three years. During the three months ended September 30, 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $3,085,000. The Notes are payable within three years of issuance and are convertible into 12,340,000 shares of the Company’s common stock. The Company also issued 12,340,000 common stock warrants to the Note holders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.65 per share for a period of three years. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $1,541,797 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and note. In addition to this discount related to the beneficial conversion feature, an additional discount of $1,532,335 recorded based on the fair value of the warrants attached to the note. This value was derived using the Black-Scholes valuation model.

1034500

4138000

0.60

487957

480236

3085000

12340000

12,340,000

0.65

1541797

1532335

Note 4– Note Payable The Company entered into a Note Purchase Agreement, dated May 12, 2015 and effective as of June 8, 2015, with Pacific Leaf Ventures, LP (“Pacific Leaf”), pursuant to which Pacific Leaf has made installment loans (the “Loans”) to the Company in the aggregate amount of $1.75 million. The purpose of the financing is to provide for the acquisition and installation of an operating facility, equipment and other tangible assets by GB Sciences Nevada, LLC (“GBSN”). Such facility and equipment was dedicated to the cultivation of cannabis and the extraction of oils and other constituents present in cannabis, subject at all times to Nevada legal requirements. The note is convertible at the option of the holder into common shares at a conversion price of $0.50, subject to anti-dilution adjustments. To evidence the Loans, the Company issued to Pacific Leaf a 6% senior secured convertible promissory note (the “Note”), bearing interest at the rate of 6% per annum, payable quarterly. All outstanding principal and interest due under the Note were due and payable on May 12, 2020. The Company was required to prepay the outstanding principal amount of the Note on a quarterly basis in an amount equal to 50% of the cash flow (accrued EBITDA) of GBSN attributable to our percentage interest in GBSN no later than the earlier to occur of (a) the fifth (5th) business day following receipt of a distribution of the Company's Share of GBSN’s EBITDA for the calendar quarter in question, or (b) thirty (30) days following the end of the calendar quarter in question, with the first such prepayment to be made not later than July 31, 2015 with respect to the quarter ending June 30, 2015. In order to induce the Pacific Leaf to extend the loan to the Company and to secure the payment and performance of all of the Secured Obligations, the Company agreed to grant Pacific Leaf a security interest in certain of its assets and enter into the lending agreement. On February 8, 2016, the Company entered into the Amended and Restated 6% Senior Convertible Promissory Note (“Amended Note”) with Pacific Leaf. The amended agreement modifies the 6% Senior Secure Convertible Promissory Note dated May 12, 2015 and effective as of June 8, 2015, in the principal amount of $1.75 million. Per the terms of the amended agreement, Pacific Leaf may make up to $1.0 million in additional advances to the Company under the Amended Note bringing the total in the aggregate to $2.75 million. The note is convertible at the option of the holder into common shares at a conversion price of $0.25, subject to anti-dilution adjustments. The Company has an option to prepay the Amended Note, without premium or penalty, in whole or in part, with accrued interest to the date of such prepayment. Until the payment in full of the Amended Note, Pacific Leaf or its designee have the option (the “Option”) to purchase up to a 20% membership interest in GBSN for a purchase price equal to $100,000 for each 2% of membership interest purchased (i.e., $1,000,000 if the Option is exercised in full), provided that the Option may not be exercised for less than a 1% membership interest in GBSN. In connection with the Amended Note, the Company also entered into the Amended and Restated Royalty Agreement with Pacific Leaf dated and effective as of February 8, 2016. Per the terms of the Amended Royalty Agreement, the royalty rate at any time shall equal to the sum of (i) 9.1%, and (ii) the percentage calculated by dividing the amount advanced in excess of $1.75 million by $1.0 million, multiplied by the gross revenues of GBSN. On the earlier of (i) the seventh anniversary of the royalty payment date, or (ii) the date that all amounts outstanding under the Amended Note have been paid in full, the royalty rate shall be reduced by 50%. On June 13, 2016, the Company received notice from the Pacific Leaf that it had elected to convert $500,000 of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 2,000,000 shares of its common stock ($500,000 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness pursuant to the Note was reduced by $500,000. On August 4, 2016, the Company entered into the Second Omnibus Amendment ("Second Amendment") of its existing agreements with Pacific Leaf. The Second Amendment eliminates Pacific Leaf's option to purchase up to a 20% membership interest in GBSN and reduces Pacific Leaf's existing royalty rate to 16.4% of the gross sales revenue of GBSN. It also caps maximum aggregate royalty payments to be made to Pacific Leaf at $2,420,000 with respect to any calendar year. In consideration of the amended terms, Pacific Leaf and its designees received 1,000,000 shares of the Company's common stock and a five-year warrant to purchase 1,500,000 shares of the Company's common stock at $0.36 per share resulting in related expense of approximately $0.9 million. On October 4, October 20, November 1, and November 10, 2016, the Company received notices the Pacific Leaf that it had elected to convert total of $1,776,750 of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 7,107,000 shares of its common stock ($1,776,750 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness pursuant to the Note was reduced by $1,776,750. On January 24, and February 22, 2017, the Company received additional notices from Pacific Leaf Ventures, LP (“Pacific Leaf”) that it had elected to convert $413,085 ($317,938 in principal and $95,145 in accrued interest) of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 1,652,332 shares of its common stock ($413,083 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness pursuant to the Note was reduced to $0.2 million. On May 12, 2017, the Company received notice from Pacific Leaf Ventures, LP (“Pacific Leaf”) that it had elected to convert $184,805 ($154,805 principal and $30,000 accrued interest) of the Company’s indebtedness to Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Note was reduced by $184,805.

1750000

0.50

0.06

2020-05-12

1750000

500000

0.06

2000000

500000

0.25

The Second Amendment eliminates Pacific Leaf's option to purchase up to a 20% membership interest in GBSN and reduces Pacific Leaf's existing royalty rate to 16.4% of the gross sales revenue of GBSN. It also caps maximum aggregate royalty payments to be made to Pacific Leaf at $2,420,000 with respect to any calendar year

1000000

1500000

0.36

900000

1776750

0.06

7107000

1776750

0.25

413085

317938

95145

0.06

1652332

413083

0.25

200000

184805

154805

30000

0.06

Note 5 – Capital Lease In July 2016, an entity associated with Pacific Leaf Partners, LLC completed the purchase of the building housing the Company’s cultivation facility at 3550 W. Teco Ave., Las Vegas, NV. In connection with the purchase, the Company entered into the Amended Lease Agreement for an initial term of ten and a half years with one option to extend the lease for five years, or until December 31, 2030. The monthly rent payments per the Amended Lease Agreement are $40,000 through December 31, 2017. Commencing January 1, 2018, the monthly rent payments will increase by 3% per annum through the expiration of the lease. The Company analyzed the transaction in accordance with the applicable accounting guidance determining that the aggregate amount of $3.9 million met the requirements for capitalization. The building has been capitalized and is included in property and equipment, net balance with related obligations included as part of current and non-current liabilities. The obligation recorded is based upon the present value of the future minimum lease payments discounted at an 11.6% interest rate. In August 2017, GB Sciences Louisiana, LLC entered into the Lease Agreement with Petroleum Drive Investment, LLC for 36,125 square feet of interior space on approximately 5.38 acres of land located at 18350 Petroleum Drive, Baton Rouge, LA 70809. The Lease Agreement is for an initial term of five years with two options to extend the lease for five years, or until June 30, 2032. The monthly rent payments per the Lease Agreement are $25,588 through June 30, 2022. If the Company exercises its first and second options to extend, monthly rent payments will increase to $28,147 beginning August 1, 2022, and to $30,966 beginning August 1, 2027. The Company analyzed the transaction in accordance with the applicable accounting guidance determining that the aggregate amount of $2.5 million met the requirements for capitalization. The building has been capitalized and is included in property and equipment, net balance with related obligations included as part of current and non-current liabilities. The obligation recorded is based upon the present value of the future minimum lease payments discounted at a 10.2% interest rate.

40000

Commencing January 1, 2018, the monthly rent payments will increase by 3% per annum through the expiration of the lease

3900000

0.116

36125

5.38

25588

2500000

0.102

Note 6 – Capital Transactions During the six months ended September 30, 2017, the Company issued an aggregate of 3,520,613 shares of common stock, as follows: <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt"></kbd>The Company issued 2,191,994 shares of its common stock to a third-party brokerage firm as a result of a cashless exercise of 2,281,000 compensation warrants at the exercise price of $0.01 per share and recorded a related expense of $0.6 million <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt"></kbd>On May 12, 2017, the Company received notice from Pacific Leaf Ventures, LP (“Pacific Leaf”) that it had elected to convert $184,805 ($154,805 principal and $30,000 accrued interest) of the Company’s indebtedness to Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory. Accordingly, the Company has issued 739,220 shares of its common stock ($184,805 converted at a price of $0.25 per share) to Pacific Leaf and the Company’s indebtedness to Pacific Leaf pursuant to the Note has been reduced by $184,805. <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt"></kbd>The Company issued 485,871 shares in exchange for consulting services and recorded a related expense of $0.1 million. The Company also issued 82,528 shares of common stock to employees and recorded an expense of $0.02 million. <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt"></kbd>The Company issued 21,000 shares of its common stock in connection with the exercise of warrants at $0.20 per share. Options and Warrants During the six months ended September 30, 2017, the Company issued 550,000 stock options under the 2014 Equity Incentive Plan to various consultants. The options are exercisable upon vesting for a period of 10 years from issuance at an exercise price ranging from $0.24 to $0.35 per share per share. The Company has recognized total of $0.04 million in share-based compensation expense related to options vested to date. During the six months ended September 30, 2017, the Company issued 250,000 stock options under the 2014 Equity Incentive Plan to its employees. The options are exercisable upon vesting for a period of 10 years from issuance at an exercise price ranging from $0.27 to $0.28 per share per share. The Company has recognized total of $0.06 million in share-based compensation expense related to options vested to date. During the six months ended September 30, 2017, the Company issued warrants to purchase 4,138,000 shares of its common stock at the price of $0.60 per share and warrants to purchase 12,340,000 shares of its common stock at the price of $0.65 per share for the period of three years to various holders of its convertible notes. Convertible notes have combined face value of $4,119,500. The Company recorded a discount of $2,012,571 based on the fair value of the warrants attached to the notes. This value was derived using the Black-Scholes valuation model.

3520613

2191994

2281000

184805

154805

30000

0.06

739220

184805

0.25

485871

100000

82528

20000.00

21000

0.20

550000

P10Y

0.24

0.35

40000.00

4138000

0.60

12340000

0.65

4119500

2012571

Note 7 – Commitments and Contingencies On September 18, 2017 GB Sciences finalized its agreement with Louisiana State University (“LSU”) AgCenter to be the sole operator of the LSU’s medical marijuana program. The LSU Board of Supervisors entered into a five-year agreement—that has an option to renew for two additional five-year terms—with GB Sciences. The contract includes the Company’s commitment to make a minimum financial contribution to the LSU AgCenter in the amount of $3.4 million, or a 10% commission of gross receipts, in addition to annual research investments of $500,000 to the LSU AgCenter. The monetary contributions would be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, which AgCenter would retain 50% of those rights. As of September 2017, GB Sciences made payments totaling $500,000 toward its obligations under the agreement. From time to time, the Company may become involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.

3400000

0.10

500000

Note 8 – Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 58,197,413 and 39,882,413 of potentially dilutive common shares at September 30, 2017 and March 31, 2017, respectively. However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.

58197413

39882413

Note 9 – Related Party Transactions During the fiscal year ended March 31, 2017, the Company entered into a consulting contract with Quantum Shop, a Company owned by a relative of one of the Company’s executives. Per the terms of the agreement, Quantum Shop is to provide GB Sciences with research, design, development, fabrication, and production services. During the year ended March 31, 2017, the Company made a payment of $50,000 to the Quantum Shop in relation to the services provided. During the six months ended September 30, 2017, additional payments of $149,903 were made to Quantum Shop in relation to the services provided. During the year ended March 31, 2017, the Company entered into an advisory agreement with Electrum Partners, LLC, a company whose President resides on GB Sciences’ Board of Directors and serves as a Chair of the Audit Committee. The agreement has a term of one year and is renewable for a successive one-year period. During the six months ended September 30, 2017, the Company made payments totaling $75,562 to Electrum Partners, LLC and issued 283,296 shares of its restricted stock. During the six months ended September 30, 2017, the Company entered into a consulting contract with Monica Poss, a relative of one of the Company’s executives. Per the terms of the agreement, Ms. Poss is to provide GB Sciences with advisory services. The Company made payments of $10,927 and issued 17,650 shares of our common stock at an expense of $4,500 relating to services provided during the six months ended September 30, 2017.

50000

149903

75562

283296

10927

17650

4500

Note 10 – Subsequent Events Private Placement Agreement Subsequent to September 30, 2017, the Company raised additional $800,000 under an existing Placement Agent’s Agreement with a third-party brokerage firm to offer for sale a maximum of up to 6,500 units at the price of $1,000 per unit for the combined total of $6.5 million. Each unit consists of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per shares for the period of three years. As a result, the Company issued 3,200,000 warrants.

800000

an existing Placement Agent’s Agreement with a third-party brokerage firm to offer for sale a maximum of up to 6,500 units at the price of $1,000 per unit for the combined total of $6.5 million. Each unit consists of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per shares for the period of three years

3200000

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 15, 2017
Details
Registrant Name	GB SCIENCES INC
Registrant CIK	0001165320
SEC Form	10-Q
Period End date	Sep. 30, 2017
Fiscal Year End	--03-31
Trading Symbol	gblx
Tax Identification Number (TIN)	593733133
Number of common stock shares outstanding		128,300,407
Filer Category	Smaller Reporting Company
Current with reporting	Yes
Voluntary filer	No
Well-known Seasoned Issuer	No
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Contained File Information, File Number	000-55462
Entity Incorporation, State Country Name	Delaware
Entity Address, Address Line One	3550 W. Teco Avenue
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	Nevada
Entity Address, Postal Zip Code	89118
City Area Code	866
Local Phone Number	721-0297

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Mar. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 971,286	$ 2,692,953
Accounts Receivable	248,265	0
Inventory	532,752	89,037
Prepaid expenses	561,066	166,378
TOTAL CURRENT ASSETS	2,313,369	2,948,368
Property and Equipment, Net	11,296,124	8,642,677
Deposits	1,257,746	1,203,305
Other Assets	292,289	212,529
TOTAL ASSETS	15,159,528	13,006,879
CURRENT LIABILITIES:
Accounts Payable	76,235	157,152
Accrued Interest	100,294	48,969
Accrued Liabilities	605,184	468,710
Convertible Notes Payable, net of unamortized discount of $4.6 million and $1 million at September 30, 2017 and March 31, 2017, respectively	530,893	2,734
TOTAL CURRENT LIABILITIES	1,312,606	677,565
Convertible Notes Payable	507	155,312
Capital Lease Obligations	6,182,181	3,771,321
TOTAL LIABILITIES	7,495,294	4,604,198
STOCKHOLDERS' (DEFICIT)/ EQUITY:
Common Stock, $0.0001 par value, 200,000,000 shares authorized, 127,927,431 and 124,406,818 shares issued and outstanding at September 30, 2017 and March 31, 2017	12,793	12,441
Additional Paid In Capital	49,012,336	43,569,864
Accumulated Deficit	(41,490,290)	(35,257,045)
TOTAL GB SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY	7,534,839	8,325,260
Non-controlling interest	129,395	77,421
TOTAL (DEFICIT)/EQUITY	7,664,234	8,402,681
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY	$ 15,159,528	$ 13,006,879

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED BALANCE SHEETS - Parenthetical - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Details
Debt Instrument, Unamortized Discount	$ 4,600,000	$ 1,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	127,927,431	124,406,818
Common Stock, Shares, Outstanding	127,927,431	124,406,818

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Details
NET REVENUE	$ 136,646	$ 0	$ 190,745	$ 0
GENERAL AND ADMINISTRATIVE EXPENSES	2,779,370	2,197,557	5,660,035	3,405,338
LOSS FROM OPERATIONS	(2,642,724)	(2,197,557)	(5,469,290)	(3,405,338)
OTHER INCOME (EXPENSE)
Interest Expense	(530,082)	(297,929)	(786,798)	(456,460)
Other Income/(Expense)	(5,769)	(10,479)	(45,182)	(23,075)
Total other expense	(535,851)	(308,408)	(831,980)	(479,535)
Net loss	(3,178,575)	(2,505,965)	(6,301,270)	(3,884,873)
Net income/(loss) attributable to non-controlling interest	(33,495)	(38,661)	(68,025)	(76,862)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	$ (3,145,080)	$ (2,467,304)	$ (6,233,245)	$ (3,808,011)
Net loss per share - basic and diluted	$ (0.02)	$ (0.04)	$ (0.05)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	127,794,766	67,920,941	126,724,132	59,043,603

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
OPERATING ACTIVITIES:
Net loss	$ (6,301,270)	$ (3,884,873)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	385,184	137,133
Stock-based compensation	1,211,218	1,785,315
Amortization of debt discount and beneficial conversion feature	450,983	316,745
Loss on disposal	0	5,572
Changes in operating assets and liabilities:
Accounts receivable	(248,265)	0
Prepaid expenses and other assets	(394,688)	42,886
Inventory	(443,715)	0
Accounts payable	(80,917)	33,716
Accrued expenses	170,050	(129,807)
Net cash used in operating activities	(5,251,420)	(1,693,313)
INVESTING ACTIVITIES:
Purchase of property and equipment	(513,271)	(957,925)
Change in deposits and other assets	(134,561)	(21,856)
Net cash used in investing activities	(647,832)	(979,781)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	4,550	4,140,354
Proceeds from non-controlling interest	120,000	165,000
Proceeds from convertible notes payable	4,119,500	500,000
Payments to Acquire Long-term Investments	(66,465)	(94,898)
Other financing activities	0	(154)
Net cash provided by financing activities	4,177,585	4,710,302
Net change in cash and cash equivalent	(1,721,667)	2,037,208
CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD	2,692,953	34,824
CASH AND CASH EQUIVALENT AT END OF PERIOD	971,286	2,072,032
Non-cash transactions:
Stock issued to settle payables	0	590,777
Stock issued to upon conversion of long-term note payable	184,731	500,000
Stock issued to settle legal obligations	0	410,840
Capital lease obligation	2,525,000	3,900,000
Stock and warrants issued upon amendment of long-term note	$ 0	$ 875,663

XML 17 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Significant Accounting Policies

6 Months Ended

Sep. 30, 2017

Notes

Note 1 - Basis of Presentation and Significant Accounting Policies

permitted. The Company expects that adoption of this guidance will result in the recognition of rig-of-use assets and related obligations.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern

6 Months Ended

Sep. 30, 2017

Notes

Note 2 - Going Concern

Note 2 – Going Concern

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Convertible Notes

6 Months Ended

Sep. 30, 2017

Notes

Note 3 - Convertible Notes

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 4- Note Payable

6 Months Ended

Sep. 30, 2017

Notes

Note 4- Note Payable

Note 4– Note Payable

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Capital Lease

6 Months Ended

Sep. 30, 2017

Notes

Note 5 - Capital Lease

Note 5 – Capital Lease

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Capital Transactions

6 Months Ended

Sep. 30, 2017

Notes

Note 6 - Capital Transactions

Note 6 – Capital Transactions

During the six months ended September 30, 2017, the Company issued an aggregate of 3,520,613 shares of common stock, as follows:

The Company issued 21,000 shares of its common stock in connection with the exercise of warrants at $0.20 per share.

Options and Warrants

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Commitments and Contingencies

6 Months Ended

Sep. 30, 2017

Notes

Note 7 - Commitments and Contingencies

Note 7 – Commitments and Contingencies

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 8 - Loss per Share

6 Months Ended

Sep. 30, 2017

Notes

Note 8 - Loss per Share

Note 8 – Loss per Share

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 9 - Related Party Transactions

6 Months Ended

Sep. 30, 2017

Notes

Note 9 - Related Party Transactions

Note 9 – Related Party Transactions

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 10 - Subsequent Events

6 Months Ended

Sep. 30, 2017

Notes

Note 10 - Subsequent Events

Note 10 – Subsequent Events

Private Placement Agreement

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2017
Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2018. The balance sheet at March 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2017.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. These reclassifications had no effect on the reported financial position, results of operations or cash flows of the Company.
Significant Accounting Policies	Significant Accounting Policies A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2017.
Recent Accounting Pronouncements	In February 2016, the Financial Accounting Standards Board (“FASB”) issued amended accounting guidance that changes the accounting for leases and requires expanded disclosures about leasing activities. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability, measured on a discounted basis, at the commencement date for all leases with terms greater than twelve months. Lessor accounting will remain largely unchanged, other than certain targeted improvements intended to align lessor accounting with the lessee accounting model and with the updated revenue recognition guidance issued in 2014. Lessees and lessors must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The amended guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018, and early application is permitted. The Company expects that adoption of this guidance will result in the recognition of rig-of-use assets and related obligations. The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is required to adopt the guidance on January 1, 2018 and will apply the cumulative catch-up transition method. The transition adjustment to be recorded to stockholders' equity upon adoption of the new standard is not expected to be material. The Company is currently evaluating the impact of ASC 606 when adopted on its consolidated financial position and result of operations. Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern (Details) - USD ($)	6 Months Ended
Note 2 - Going Concern (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
Accumulated Deficit	$ (41,490,290)		$ (35,257,045)
Net cash used in operating activities	(5,251,420)	$ (1,693,313)
Approximate
Accumulated Deficit	41,500,000
Net cash used in operating activities	$ 5,200,000	$ 1,700,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 3 - Convertible Notes (Details)	1 Months Ended		6 Months Ended
Note 3 - Convertible Notes (Details)	Jul. 31, 2017	Mar. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares	Jun. 30, 2017 USD ($)
Debt Instrument, Unamortized Discount		$ 1,000,000	$ 4,600,000
Private Placement Terms	In July, 2017, the Company entered into a Placement Agent’s Agreement with a third-party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per share for the period of three years
Short Term Promissory Note 1
Debt Instrument, Face Amount		$ 965,500	$ 4,119,500	$ 1,034,500
Class of Warrant, Outstanding \| shares		3,862,000
Class of Warrant, Exercise Price \| $ / shares		$ 0.60	$ 0.60
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 416,733	$ 487,957
Debt Instrument, Unamortized Discount		$ 548,767	$ 2,012,571	$ 480,236
Short Term Promissory Note 1 \| Common Stock
Debt Instrument, Convertible, Number of Equity Instruments		3,862,000	4,138,000
Private Placement of 6% Convertible Promissory Notes
Debt Instrument, Face Amount			$ 3,085,000
Debt Instrument, Convertible, Number of Equity Instruments			12,340,000
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 1,541,797
Debt Instrument, Unamortized Discount			$ 1,532,335
Warrants Outstanding			12,340,000
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 0.65

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 4- Note Payable (Details) - Pacific Leaf Ventures Lp - USD ($)	1 Months Ended	2 Months Ended		3 Months Ended	6 Months Ended
	Aug. 31, 2016	Feb. 28, 2017	Nov. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	May 12, 2017	Feb. 22, 2017	Nov. 10, 2016	Feb. 08, 2016	Jun. 08, 2015
Debt Instrument, Face Amount										$ 1,750,000
Debt Instrument, Convertible, Conversion Price										$ 0.50
Debt Instrument, Interest Rate, Stated Percentage										6.00%
Debt Instrument, Maturity Date					May 12, 2020
Long-term Debt, Gross									$ 1,750,000
Debt Instrument, Convertible, Terms of Conversion Feature					Per the terms of the amended agreement, Pacific Leaf may make up to $1.0 million in additional advances to the Company under the Amended Note bringing the total in the aggregate to $2.75 million. The note is convertible at the option of the holder into common shares at a conversion price of $0.25, subject to anti-dilution adjustments
Debt Instrument, Payment Terms					Until the payment in full of the Amended Note, Pacific Leaf or its designee have the option (the “Option”) to purchase up to a 20% membership interest in GBSN for a purchase price equal to $100,000 for each 2% of membership interest purchased (i.e., $1,000,000 if the Option is exercised in full), provided that the Option may not be exercised for less than a 1% membership interest in GBSN
Royalty Agreement Amended Terms				In connection with the Amended Note, the Company also entered into the Amended and Restated Royalty Agreement with Pacific Leaf dated and effective as of February 8, 2016. Per the terms of the Amended Royalty Agreement, the royalty rate at any time shall equal to the sum of (i) 9.1%, and (ii) the percentage calculated by dividing the amount advanced in excess of $1.75 million by $1.0 million, multiplied by the gross revenues of GBSN. On the earlier of (i) the seventh anniversary of the royalty payment date, or (ii) the date that all amounts outstanding under the Amended Note have been paid in full, the royalty rate shall be reduced by 50%
Class of Warrant, Outstanding					1,500,000
Investment Warrants, Exercise Price	$ 0.36
Common Stock
Stock Issued During Period, Shares, Other	1,000,000
Warrant
Allocated Share-based Compensation Expense	$ 900,000
Short Term Promissory Note 4
Debt Instrument, Face Amount					$ 500,000
Debt Instrument, Convertible, Conversion Price					$ 0.25
Debt Instrument, Interest Rate, Stated Percentage					6.00%
Debt Conversion, Converted Instrument, Amount					$ 500,000
Short Term Promissory Note 4 \| Common Stock
Debt Conversion, Converted Instrument, Shares Issued					2,000,000
Convertible Promissory Note
Debt Instrument, Convertible, Terms of Conversion Feature					The Second Amendment eliminates Pacific Leaf's option to purchase up to a 20% membership interest in GBSN and reduces Pacific Leaf's existing royalty rate to 16.4% of the gross sales revenue of GBSN. It also caps maximum aggregate royalty payments to be made to Pacific Leaf at $2,420,000 with respect to any calendar year
Short Term Promissory Note 5
Debt Instrument, Face Amount								$ 1,776,750
Debt Instrument, Convertible, Conversion Price								$ 0.25
Debt Instrument, Interest Rate, Stated Percentage					6.00%
Debt Conversion, Converted Instrument, Amount			$ 1,776,750
Short Term Promissory Note 5 \| Common Stock
Debt Conversion, Converted Instrument, Shares Issued			7,107,000
Short Term Promissory Note 6
Debt Instrument, Face Amount							$ 413,085
Debt Instrument, Convertible, Conversion Price							$ 0.25
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Long-term Debt, Gross							$ 200,000
Debt Conversion, Converted Instrument, Amount		$ 413,083
Short Term Promissory Note 6 \| Principal
Debt Instrument, Face Amount							317,938
Short Term Promissory Note 6 \| Interest
Debt Instrument, Face Amount							$ 95,145
Short Term Promissory Note 6 \| Common Stock
Debt Conversion, Converted Instrument, Shares Issued		1,652,332
Short Term Promissory Note 7
Debt Instrument, Face Amount					$ 184,805
Debt Instrument, Convertible, Conversion Price						$ 0.25
Debt Instrument, Interest Rate, Stated Percentage					6.00%
Short Term Promissory Note 7 \| Principal
Debt Instrument, Face Amount					$ 154,805
Short Term Promissory Note 7 \| Interest
Debt Instrument, Face Amount					$ 30,000
Short Term Promissory Note 7 \| Common Stock
Debt Conversion, Converted Instrument, Shares Issued					739,220

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 5 - Capital Lease (Details) - Pacific Leaf Ventures Lp	3 Months Ended	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2017 USD ($) ft² a
Teco Facility Lease
Debt Instrument, Periodic Payment		$ 40,000
Description of Lessee Leasing Arrangements, Capital Leases	Commencing January 1, 2018, the monthly rent payments will increase by 3% per annum through the expiration of the lease
Capital Lease Obligations		$ 3,900,000
Discount Rate		11.60%
GB Sciences Louisiana Lease
Debt Instrument, Periodic Payment		$ 25,588
Capital Lease Obligations		$ 2,500,000
Discount Rate		10.20%
Area of Real Estate Property \| ft²		36,125
Area of Land \| a		5.38

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 6 - Capital Transactions (Details) - USD ($)	1 Months Ended	6 Months Ended
Note 6 - Capital Transactions (Details) - USD ($)	Aug. 31, 2016	Sep. 30, 2017	Jun. 30, 2017	May 12, 2017	Mar. 31, 2017	Jun. 08, 2015
Stock Issued During Period, Value, Issued for Services		$ 100,000
Stock Granted, Value, Share-based Compensation		20,000.00
Debt Instrument, Unamortized Discount		$ 4,600,000			$ 1,000,000
2014 Equity Incentive Plan
Options, Granted		550,000
Expiration Period		10 years
2014 Equity Incentive Plan \| Employee Stock Option
Allocated Share-based Compensation Expense		$ 40,000.00
2014 Equity Incentive Plan \| Minimum
Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.24
2014 Equity Incentive Plan \| Maximum
Options, Grants in Period, Weighted Average Grant Date Fair Value		0.35
Short Term Promissory Note 1
Class of Warrant, Exercise Price		$ 0.60			$ 0.60
Debt Instrument, Face Amount		$ 4,119,500	$ 1,034,500		$ 965,500
Debt Instrument, Unamortized Discount		$ 2,012,571	$ 480,236		$ 548,767
Private Placement of 6% Convertible Promissory Notes
Debt Instrument, Convertible, Conversion Price		$ 0.65
Debt Instrument, Face Amount		$ 3,085,000
Debt Instrument, Unamortized Discount		1,532,335
Pacific Leaf Ventures Lp
Debt Instrument, Interest Rate, Stated Percentage						6.00%
Debt Instrument, Convertible, Conversion Price						$ 0.50
Debt Instrument, Face Amount						$ 1,750,000
Pacific Leaf Ventures Lp \| Short Term Promissory Note 7
Debt Conversion, Original Debt, Amount		$ 184,805
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Convertible, Conversion Price				$ 0.25
Debt Instrument, Face Amount		$ 184,805
Pacific Leaf Ventures Lp \| Short Term Promissory Note 7 \| Principal
Debt Conversion, Original Debt, Amount		154,805
Debt Instrument, Face Amount		154,805
Pacific Leaf Ventures Lp \| Short Term Promissory Note 7 \| Interest
Debt Conversion, Original Debt, Amount		30,000
Debt Instrument, Face Amount		$ 30,000
Common Stock
Stock Issued During Period, Shares, New Issues		3,520,613
Stock Issued During Period, Shares, Issued for Services		485,871
Stock Issued During Period, Shares, Share-based Compensation		82,528
Common Stock \| A third-party brokerage firm
Stock Issued During Period, Shares, New Issues		2,191,994
Common Stock \| Pacific Leaf Ventures Lp \| Short Term Promissory Note 7
Debt Conversion, Converted Instrument, Shares Issued		739,220
Warrant
Stock Issued During Period, Shares, New Issues		21,000
Class of Warrant, Exercise Price		$ 0.20
Warrant \| Short Term Promissory Note 1
Class of Warrant, Exercise Price		$ 0.60
Non-Option Equity Instruments, Granted		4,138,000
Warrant \| Private Placement of 6% Convertible Promissory Notes
Class of Warrant, Exercise Price		$ 0.65
Non-Option Equity Instruments, Granted		12,340,000
Warrant \| A third-party brokerage firm
Non-Option Equity Instruments, Exercised		2,281,000
Warrant \| Pacific Leaf Ventures Lp
Allocated Share-based Compensation Expense	$ 900,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 7 - Commitments and Contingencies (Details) - LSU AgCenter	6 Months Ended
	Sep. 30, 2017 USD ($)
Minimum Financial Contribution
Other Commitment	$ 3,400,000
Gross receipts, commission	10.00%
Annual Research Investments
Other Commitment	$ 500,000
Research and Development Expense	$ 500,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 8 - Loss per Share (Details) - shares	6 Months Ended	12 Months Ended
Note 8 - Loss per Share (Details) - shares	Sep. 30, 2017	Mar. 31, 2017
Details
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,197,413	39,882,413

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 9 - Related Party Transactions (Details) - USD ($)	6 Months Ended	12 Months Ended
Note 9 - Related Party Transactions (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Stock Issued During Period, Value, Issued for Services	$ 100,000
Officer
Related Party Transaction, Amounts of Transaction	$ 10,927
Stock Issued During Period, Shares, Issued for Services	17,650
Stock Issued During Period, Value, Issued for Services	$ 4,500
Quantum Shop
Related Party Transaction, Amounts of Transaction	149,903	$ 50,000
Electrum Partners LLC
Related Party Transaction, Amounts of Transaction	$ 75,562
Stock Issued During Period, Shares, Issued for Services	283,296

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 10 - Subsequent Events (Details) - USD ($)		1 Months Ended	6 Months Ended
Note 10 - Subsequent Events (Details) - USD ($)	Aug. 11, 2017	Jul. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Proceeds from convertible notes payable			$ 4,119,500	$ 500,000
Private Placement Terms		In July, 2017, the Company entered into a Placement Agent’s Agreement with a third-party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per share for the period of three years
Subsequent Event
Proceeds from convertible notes payable	$ 800,000
Private Placement Terms		an existing Placement Agent’s Agreement with a third-party brokerage firm to offer for sale a maximum of up to 6,500 units at the price of $1,000 per unit for the combined total of $6.5 million. Each unit consists of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per shares for the period of three years
Subsequent Event \| Warrant
Non-Option Equity Instruments, Granted	3,200,000

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 82 145 1 false 27 0 false 6 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS Sheet http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS CONSOLIDATED CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 000030 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS - Parenthetical Sheet http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS - Parenthetical Statements 3 false false R4.htm 000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 000060 - Disclosure - Note 1 - Basis of Presentation and Significant Accounting Policies Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPolicies Note 1 - Basis of Presentation and Significant Accounting Policies Notes 6 false false R7.htm 000070 - Disclosure - Note 2 - Going Concern Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcern Note 2 - Going Concern Notes 7 false false R8.htm 000080 - Disclosure - Note 3 - Convertible Notes Notes http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotes Note 3 - Convertible Notes Notes 8 false false R9.htm 000090 - Disclosure - Note 4- Note Payable Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayable Note 4- Note Payable Notes 9 false false R10.htm 000100 - Disclosure - Note 5 - Capital Lease Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLease Note 5 - Capital Lease Notes 10 false false R11.htm 000110 - Disclosure - Note 6 - Capital Transactions Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactions Note 6 - Capital Transactions Notes 11 false false R12.htm 000120 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingencies Note 7 - Commitments and Contingencies Notes 12 false false R13.htm 000130 - Disclosure - Note 8 - Loss per Share Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShare Note 8 - Loss per Share Notes 13 false false R14.htm 000140 - Disclosure - Note 9 - Related Party Transactions Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactions Note 9 - Related Party Transactions Notes 14 false false R15.htm 000150 - Disclosure - Note 10 - Subsequent Events Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEvents Note 10 - Subsequent Events Notes 15 false false R16.htm 000160 - Disclosure - Note 1 - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies Note 1 - Basis of Presentation and Significant Accounting Policies (Policies) Policies http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPolicies 16 false false R17.htm 000170 - Disclosure - Note 2 - Going Concern (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails Note 2 - Going Concern (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcern 17 false false R18.htm 000180 - Disclosure - Note 3 - Convertible Notes (Details) Notes http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails Note 3 - Convertible Notes (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotes 18 false false R19.htm 000190 - Disclosure - Note 4- Note Payable (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails Note 4- Note Payable (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayable 19 false false R20.htm 000200 - Disclosure - Note 5 - Capital Lease (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails Note 5 - Capital Lease (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLease 20 false false R21.htm 000210 - Disclosure - Note 6 - Capital Transactions (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails Note 6 - Capital Transactions (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactions 21 false false R22.htm 000220 - Disclosure - Note 7 - Commitments and Contingencies (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails Note 7 - Commitments and Contingencies (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingencies 22 false false R23.htm 000230 - Disclosure - Note 8 - Loss per Share (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShareDetails Note 8 - Loss per Share (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShare 23 false false R24.htm 000240 - Disclosure - Note 9 - Related Party Transactions (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails Note 9 - Related Party Transactions (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactions 24 false false R25.htm 000250 - Disclosure - Note 10 - Subsequent Events (Details) Sheet http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails Note 10 - Subsequent Events (Details) Details http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEvents 25 false false All Reports Book All Reports gblx-20170930.htm gblx-20170930.xsd gblx-20170930_cal.xml gblx-20170930_def.xml gblx-20170930_lab.xml gblx-20170930_pre.xml gblx_ex31z1.htm gblx_ex31z2.htm gblx_ex32z1.htm gblx_ex32z2.htm http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gblx-20170930.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 82, "dts": { "calculationLink": { "local": [ "gblx-20170930_cal.xml" ] }, "definitionLink": { "local": [ "gblx-20170930_def.xml" ] }, "inline": { "local": [ "gblx-20170930.htm" ] }, "labelLink": { "local": [ "gblx-20170930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-doc-2017-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml" ] }, "presentationLink": { "local": [ "gblx-20170930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-ref-2017-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml" ] }, "schema": { "local": [ "gblx-20170930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-parts-codification-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" ] } }, "elementCount": 214, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2014-01-31": 10, "total": 10 }, "keyCustom": 6, "keyStandard": 139, "memberCustom": 20, "memberStandard": 7, "nsprefix": "fil", "nsuri": "http://gbsciences.com/20170930", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010 - Document - Document and Entity Information", "role": "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000100 - Disclosure - Note 5 - Capital Lease", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLease", "shortName": "Note 5 - Capital Lease", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000110 - Disclosure - Note 6 - Capital Transactions", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactions", "shortName": "Note 6 - Capital Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000120 - Disclosure - Note 7 - Commitments and Contingencies", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingencies", "shortName": "Note 7 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000130 - Disclosure - Note 8 - Loss per Share", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShare", "shortName": "Note 8 - Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000140 - Disclosure - Note 9 - Related Party Transactions", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactions", "shortName": "Note 9 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000150 - Disclosure - Note 10 - Subsequent Events", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEvents", "shortName": "Note 10 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000160 - Disclosure - Note 1 - Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Note 1 - Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "E17Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000170 - Disclosure - Note 2 - Going Concern (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails", "shortName": "Note 2 - Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html" ], "contextRef": "E17Q3_StScenario-Approximate", "decimals": "INF", "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "E17Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000180 - Disclosure - Note 3 - Convertible Notes (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "shortName": "Note 3 - Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "contextRef": "E17Q1_DebtInstr-ShortTermPromissoryNote1", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "contextRef": "I150608_LegalEntity-PacificLeafVenturesLp", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000190 - Disclosure - Note 4- Note Payable (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "shortName": "Note 4- Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930_LegalEntity-PacificLeafVenturesLp", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "E17Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000020 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS", "role": "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS", "shortName": "CONSOLIDATED CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "E17Q3", "decimals": "INF", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930_LegalEntity-PacificLeafVenturesLp_LeaseArrangementType-TecoFacilityLease", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000200 - Disclosure - Note 5 - Capital Lease (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails", "shortName": "Note 5 - Capital Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930_LegalEntity-PacificLeafVenturesLp_LeaseArrangementType-TecoFacilityLease", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000210 - Disclosure - Note 6 - Capital Transactions (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "shortName": "Note 6 - Capital Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "lang": null, "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "contextRef": "E17Q3_LegalEntity-LsuAgcenter_OtherCommitments-MinimumFinancialContribution", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000220 - Disclosure - Note 7 - Commitments and Contingencies (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails", "shortName": "Note 7 - Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "contextRef": "E17Q3_LegalEntity-LsuAgcenter_OtherCommitments-MinimumFinancialContribution", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000230 - Disclosure - Note 8 - Loss per Share (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShareDetails", "shortName": "Note 8 - Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000240 - Disclosure - Note 9 - Related Party Transactions (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails", "shortName": "Note 9 - Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "contextRef": "D170401_170930_RelPtyTrnsByRelPty-Officer", "decimals": "INF", "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000250 - Disclosure - Note 10 - Subsequent Events (Details)", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "shortName": "Note 10 - Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "contextRef": "D170811_SubsequentEventType-SubsequentEvent", "decimals": "INF", "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "E17Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000030 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS - Parenthetical", "role": "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED CONDENSED BALANCE SHEETS - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "E17Q3", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "Y17Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "Y17Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": "INF", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - Note 1 - Basis of Presentation and Significant Accounting Policies", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Note 1 - Basis of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - Note 2 - Going Concern", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcern", "shortName": "Note 2 - Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000080 - Disclosure - Note 3 - Convertible Notes", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotes", "shortName": "Note 3 - Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000090 - Disclosure - Note 4- Note Payable", "role": "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayable", "shortName": "Note 4- Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "contextRef": "D170401_170930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 27, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContainedFileInformationFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The SEC Document Number of the contained file.", "label": "Contained File Information, File Number" } } }, "localname": "ContainedFileInformationFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Fiscal Year End" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Period End date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "SEC Form" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Registrant CIK" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Number of common stock shares outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Current with reporting" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "State or Country Name where an entity is incorporated", "label": "Entity Incorporation, State Country Name" } } }, "localname": "EntityIncorporationStateCountryName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Tax Identification Number (TIN)" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "nineDigitItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Voluntary filer" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "fil_AThirdPartyBrokerageFirmMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "A third-party brokerage firm" } } }, "localname": "AThirdPartyBrokerageFirmMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_AnnualResearchInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Annual Research Investments, during the indicated time period.", "label": "Annual Research Investments" } } }, "localname": "AnnualResearchInvestmentsMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "fil_ApproximateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Approximate" } } }, "localname": "ApproximateMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails" ], "xbrltype": "domainItemType" }, "fil_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Convertible Promissory Note" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "domainItemType" }, "fil_ElectrumPartnersLlcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Electrum Partners LLC" } } }, "localname": "ElectrumPartnersLlcMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_GbSciencesLouisianaLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock and warrants issued upon amendment of long-term note", "label": "GB Sciences Louisiana Lease" } } }, "localname": "GbSciencesLouisianaLeaseMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "domainItemType" }, "fil_GrossReceiptsCommission": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Gross receipts, commission, during the indicated time period.", "label": "Gross receipts, commission" } } }, "localname": "GrossReceiptsCommission", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "fil_InterestMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Interest" } } }, "localname": "InterestMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_LsuAgcenterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the LSU AgCenter, during the indicated time period.", "label": "LSU AgCenter" } } }, "localname": "LsuAgcenterMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "fil_MinimumFinancialContributionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Minimum Financial Contribution, during the indicated time period.", "label": "Minimum Financial Contribution" } } }, "localname": "MinimumFinancialContributionMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "fil_N2014EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Short Term Notes and Interest Bearing Advance", "label": "2014 Equity Incentive Plan" } } }, "localname": "N2014EquityIncentivePlanMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_PacificLeafVenturesLpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Pacific Leaf Ventures Lp" } } }, "localname": "PacificLeafVenturesLpMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_PrincipalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Principal" } } }, "localname": "PrincipalMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_PrivatePlacementOf6ConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock and warrants issued upon amendment of long-term note", "label": "Private Placement of 6% Convertible Promissory Notes" } } }, "localname": "PrivatePlacementOf6ConvertiblePromissoryNotesMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_PrivatePlacementTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the description of Private Placement Terms, during the indicated time period.", "label": "Private Placement Terms" } } }, "localname": "PrivatePlacementTerms", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "fil_QuantumShopMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Quantum Shop, during the indicated time period.", "label": "Quantum Shop" } } }, "localname": "QuantumShopMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_RoyaltyAgreementAmendedTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the description of Royalty Agreement Amended Terms, during the indicated time period.", "label": "Royalty Agreement Amended Terms" } } }, "localname": "RoyaltyAgreementAmendedTerms", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "stringItemType" }, "fil_ShortTermPromissoryNote1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Short Term Promissory Note 1" } } }, "localname": "ShortTermPromissoryNote1Member", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_ShortTermPromissoryNote4Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Short Term Promissory Note 4" } } }, "localname": "ShortTermPromissoryNote4Member", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "domainItemType" }, "fil_ShortTermPromissoryNote5Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Short Term Promissory Note 5" } } }, "localname": "ShortTermPromissoryNote5Member", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "domainItemType" }, "fil_ShortTermPromissoryNote6Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued for modification of notes payable", "label": "Short Term Promissory Note 6" } } }, "localname": "ShortTermPromissoryNote6Member", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "domainItemType" }, "fil_ShortTermPromissoryNote7Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Short Term Notes and Interest Bearing Advance", "label": "Short Term Promissory Note 7" } } }, "localname": "ShortTermPromissoryNote7Member", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "fil_StockAndWarrantsIssuedUponAmendmentOfLongTermNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monetary amount of Stock and warrants issued upon amendment of long-term note, during the indicated time period.", "label": "Stock and warrants issued upon amendment of long-term note" } } }, "localname": "StockAndWarrantsIssuedUponAmendmentOfLongTermNote", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "fil_StockIssuedToSettleLegalObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monetary amount of Stock issued to settle legal obligations, during the indicated time period.", "label": "Stock issued to settle legal obligations" } } }, "localname": "StockIssuedToSettleLegalObligations", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "fil_StockIssuedToUponConversionOfLongTermNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monetary amount of Stock issued to upon conversion of long-term note payable, during the indicated time period.", "label": "Stock issued to upon conversion of long-term note payable" } } }, "localname": "StockIssuedToUponConversionOfLongTermNotePayable", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "fil_TecoFacilityLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock and warrants issued upon amendment of long-term note", "label": "Teco Facility Lease" } } }, "localname": "TecoFacilityLeaseMember", "nsuri": "http://gbsciences.com/20170930", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "domainItemType" }, "invest_InvestmentWarrantsExercisePrice": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Exercise price of the warrants.", "label": "Investment Warrants, Exercise Price" } } }, "localname": "InvestmentWarrantsExercisePrice", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable {1}", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r18", "r24" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities {1}", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r102", "r109", "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r45", "r55", "r129" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount and beneficial conversion feature" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of land held.", "label": "Area of Land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "areaItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r149", "r163" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "TOTAL ASSETS", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r40" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "TOTAL CURRENT ASSETS", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r103", "r110" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Note 1 - Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligations": { "auth_ref": [ "r15", "r136", "r164" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.", "label": "Capital Lease Obligations" } } }, "localname": "CapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r35", "r135", "r136" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations {1}", "terseLabel": "Capital Lease Obligations" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for capital leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Note 5 - Capital Lease" } } }, "localname": "CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLease" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r25", "r57" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENT AT END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r51", "r127" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Net change in cash and cash equivalent", "totalLabel": "Net change in cash and cash equivalent" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r65" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant, Exercise Price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstanding": { "auth_ref": [ "r64" ], "lang": { "en-US": { "role": { "documentation": "This item provides the title of issue of securities called for by warrants or rights outstanding.", "label": "Warrants Outstanding" } } }, "localname": "ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r88", "r154", "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r87", "r89" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Note 7 - Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r92" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.0001 par value, 200,000,000 shares authorized, 127,927,431 and 124,406,818 shares issued and outstanding at September 30, 2017 and March 31, 2017" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r63", "r117", "r123", "r124" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Note 3 - Convertible Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r35" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable {1}", "terseLabel": "Convertible Notes Payable" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, net of unamortized discount of $4.6 million and $1 million at September 30, 2017 and March 31, 2017, respectively" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r60", "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r60", "r62" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r60", "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Note 4- Note Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r150", "r151", "r161" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r151", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt Instrument, Convertible, Beneficial Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r34", "r93", "r94", "r96" ], "lang": { "en-US": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "Debt Instrument, Convertible, Number of Equity Instruments" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r34", "r93", "r95", "r96" ], "lang": { "en-US": { "role": { "documentation": "Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r130", "r132" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r33", "r160" ], "lang": { "en-US": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r35", "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r129", "r132" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical", "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecurityAxis": { "auth_ref": [ "r74", "r76", "r77", "r78", "r79", "r125", "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Information by types of debt securities.", "label": "Debt Security [Axis]" } } }, "localname": "DebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits {1}", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r55", "r83" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases": { "auth_ref": [ "r86", "r133", "r134" ], "lang": { "en-US": { "role": { "documentation": "A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Description of Lessee Leasing Arrangements, Capital Leases" } } }, "localname": "DescriptionOfLesseeLeasingArrangementsCapitalLeases", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Notes" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r82", "r85" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Loss on disposal", "negatedLabel": "Loss on disposal" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Note 8 - Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote8LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsDiscountRate": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.", "label": "Discount Rate" } } }, "localname": "FairValueInputsDiscountRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "GENERAL AND ADMINISTRATIVE EXPENSES" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Accounts receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Change in deposits and other assets", "negatedLabel": "Change in deposits and other assets" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Inventory {1}", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Prepaid expenses and other assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r128", "r131", "r156" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r29" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r39", "r80" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "TOTAL LIABILITIES", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r153", "r167" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r60", "r61", "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Capital lease obligation" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "TOTAL CURRENT LIABILITIES", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_MajorTypesOfDebtSecuritiesDomain": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Provides general categories of investments for which information is required or determined to be disclosed.", "label": "Major Types of Debt Securities" } } }, "localname": "MajorTypesOfDebtSecuritiesDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r38", "r152", "r166" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r51", "r53" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r51", "r53" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash used in investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r52", "r56" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r56", "r69", "r155", "r170" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.", "totalLabel": "NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r118", "r121" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net income/(loss) attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Total other expense", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OfficerMember": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Executive of the entity that is appointed to the position by the board of directors.", "label": "Officer" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "LOSS FROM OPERATIONS", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r12", "r148", "r162" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Income/(Expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "auth_ref": [], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.", "label": "Payments to Acquire Long-term Investments", "negatedLabel": "Payments to Acquire Long-term Investments" } } }, "localname": "PaymentsToAcquireLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r47" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Purchase of property and equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r103", "r110" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r81" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r49" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r48" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r50" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from non-controlling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r58", "r59" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r116", "r118", "r119", "r121", "r122" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r84", "r168" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Reclassifications": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.", "label": "Reclassifications" } } }, "localname": "Reclassifications", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r138", "r141", "r142" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r139", "r141", "r142", "r143", "r144" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Note 9 - Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r113", "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r98", "r165" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r42" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "NET REVENUE" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r54" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Non-Option Equity Instruments, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Non-Option Equity Instruments, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r101", "r105" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r104" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expiration Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r37", "r92" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcernDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote3ConvertibleNotesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote5CapitalLeaseDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote7CommitmentsAndContingenciesDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r100", "r112" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Stock Granted, Value, Share-based Compensation" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r60", "r61", "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock issued to settle payables" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r92", "r98" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r92", "r98" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote9RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r75" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "TOTAL GB SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY", "totalLabel": "TOTAL GB SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "STOCKHOLDERS' (DEFICIT)/ EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r114", "r115", "r120" ], "calculation": { "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "TOTAL (DEFICIT)/EQUITY", "totalLabel": "TOTAL (DEFICIT)/EQUITY" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Note 6 - Capital Transactions" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Note 10 - Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Note 2 - Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote2GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Non-cash transactions:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Details" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r71", "r72", "r73" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote1BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_DisclosureNote10SubsequentEventsDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote4NotePayableDetails", "http://gbsciences.com/20170930/role/idr_DisclosureNote6CapitalTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://gbsciences.com/20170930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=95456744&loc=d3e3913-113898" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4568447-111683" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=d3e5614-111684" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=6435544&loc=d3e41834-113960" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84176918&loc=d3e32400-112679" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164451&loc=d3e36991-112694" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/subtopic&trid=2209026" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)-(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r172": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r173": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column A" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3095-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6061-108592" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6132-108592" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6143-108592" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5086-111524" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27405-111563" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2443-110228" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77904769&loc=SL2265659-115463" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" } }, "version": "2.0" } ZIP 44 0001445866-17-001661-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001445866-17-001661-xbrl.zip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end